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1. Abstract 
The centrosome is known as the coordinator of key organizational processes of a cell. 
Mutations in genes of centrosome associated proteins have been found to cause primary 
microcephaly (MCPH) or related growth pathologies such as microcephalic primordial 
dwarfism syndromes in humans. Defects in mitotic progression, chromosome segregation, 
microtubule assembly and DNA damage-induced checkpoint arrests are the proposed links for 
the underlying mechanisms. Genes that are part of networks involved in the regulation of the 
cell cycle can be potential candidates for both diseases. To identify new genes involved in the 
disease process, twenty nine consanguineous MCPH families and a family with microcephalic 
primordial dwarfism were recruited from various areas of Pakistan. Homozygosity mapping 
complemented with exome sequencing or targeted gene sequencing identified several 
mutations in known MCPH associated genes and in a new gene, PLK4. In case of MCPH, 
mutations were identified in 28 families linked to known loci. In one family sequencing of the 
whole exome failed to detect a mutation, suggesting the involvement of regulatory regions. 
Nine novel mutations were found in ASPM, two in MCPH1 and two in CDK5RAP2. Three 
known mutations were found in ASPM and one in WDR62. Furthermore, the exact breakpoints 
were mapped in two families carrying overlapping homozygous microdeletions of 164 kb and 
577 kb at the MCPH1 locus. 
A biallelic loss-of-function mutation, p.Arg936Serfs*1, was identified near the C-terminus of 
PLK4 in a family segregating inherited microcephalic primordial dwarfism. PLK4 kinase is an 
essential regulator of centriole biogenesis. Cellular experiments carried out with patient-
derived fibroblasts demonstrated a significant reduction at the protein level. Centriole 
biogenesis was significantly impaired and resulted in monopolar configurations, centriole loss 
and defective spindle formation. Further, overexpression studies revealed that mutant PLK4 
still localized to the centrosome but centriole duplication was significantly impaired. Moreover, 
patient cells showed a reduced cellular proliferation and delayed mitotic progression. 
Combining genetic data with the results of cellular experiments, PLK4 was established as a 
new disease-associated gene in microcephalic primordial dwarfism. 
This study adds to the mutational spectra of MCPH-associated genes and quantifies the 
genetic heterogeneity in the Pakistani population. It further confirms the importance of the 
centrosome for normal brain and body size and extends the genetic understanding and 
phenotypic spectrum associated with genes relevant for centriole biogenesis. 
Zusammenfassung 
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2. Zusammenfassung 
Zentrale organisatorische Prozesse der Zelle werden vom Zentrosom koordiniert. Tragen die 
Gene, die für zentrosomassoziierte Proteine kodieren, Mutationen, so kann das zu primärer 
Mikrozephalie (MCPH) oder ähnlichen Wachstumsstörungen, wie z. B. den mikrozephalen 
primordialen Kleinwuchssyndromen (MPD), führen. Die zugrundeliegenden Defekte führen zu 
Störungen der mitotischen Progression, der Chromosomensegregation und der Mikrotubuli-
Anordnung sowie zu Arretierungen an Zellzykluskontrollpunkten, die mit DNA-Schäden im 
Zusammenhang stehen. Grundsätzlich sind alle Gene für Komponenten von Netzwerken, die 
den Zellzyklus regulieren, potentielle Kandidaten für die Verwicklung in die Ausprägung 
derartiger Erkrankungen. Um neue involvierte Gene zu identifizieren, wurden 29 konsanguine 
MCPH-Familien und eine MPD-Familie aus verschiedenen Regionen Pakistans rekrutiert. Mit 
Hilfe von Homozygotie-Kartierungen ergänzt mit Exom- bzw. Kandidatengen-
Sequenzierungen konnten verschiedene Mutationen in bekannten MCPH-assoziierten Genen 
sowie in einem neuen Gen (PLK4) identifiziert werden. Bezogen auf MCPH wurden in 28 
Familien, die mit bekannten Loci koppelten, Mutationen gefunden. In einer Familie konnte die 
kausale Mutation trotz der Sequenzierung des gesamten Exoms nicht detektiert werden. Hier 
könnte die Mutation in einer der nicht erfassten regulatorischen Regionen liegen. Es wurden 
zahlreiche neue Mutationen gefunden, neun in ASPM, zwei in MCPH1 und weitere zwei in 
CDK5RAP2. Weiterhin wurden drei bekannte Mutationen in dem Gen ASPM und eine 
bekannte Mutation in WDR62 gefunden. Darüber hinaus konnten in zwei Familien die genauen 
Bruchpunkte einer 164-kb- und einer 577-kb-Deletion am MCPH1-Locus kartiert werden, die 
einander überlappten und in den jeweiligen Familien homozygot vorlagen. 
In der MPD-Familie wurde in der Nähe des C-Terminus von PLK4 die biallelische 
Funktionsverlustmutation p.Arg936SerFs*1 identifiziert. Die PLK4-Kinase ist ein essentieller 
Regulator der Centriol-Biogenese. Fibroblastenzellen von betroffenen Probanden wiesen eine 
signifikant reduzierte Proteinmenge auf. Außerdem war die Centriol-Biogenese stark 
beeinträchtigt. Dies resultierte in monopolaren Strukturen, einem Verlust von Centriolen und 
einer fehlerhaften Spindelbildung. Des Weiteren haben Überexpressionsstudien gezeigt, dass 
das mutierte PLK4-Protein zwar noch zum Zentrosom lokalisiert, jedoch die Fähigkeit der 
Kinase, die Centriol-Duplikation zu befördern, signifikant eingeschränkt ist. Darüber hinaus 
zeigten die Patientenzellen eine reduzierte Proliferation und eine verzögerte mitotische 
Progression. Die genetischen Daten zusammen mit den Resultaten der zellulären 
Experimente haben PLK4 überzeugend als ein neues MPD-assoziiertes Gen etabliert. 
Die vorliegende Studie erweitert die Mutationsspektren einiger MCPH-assoziierter Gene und 
quantifiziert die genetische Heterogenität in der Pakistanischen Bevölkerung hinsichtlich der 
Zusammenfassung 
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untersuchten seltenen Erkrankungen. Diese Arbeit bestätigt außerdem die große Bedeutung 
der Zentrosomenfunktion für eine normale Gehirnentwicklung und Körpergröße. Sie erweitert 
ferner unser Wissen über die für die Centriol-Biogenese relevanten Gene sowie das 
phänotypische Spektrum, das mit diesen assoziiert sein kann. 
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3.Introduction 
The word ‘genetics’ was coined by William Bateson after the rediscovery of Gregory Mendel’s 
work at the beginning of the 20th century (Harper 2005). Archibald Garrod established the first 
link between a medical condition and Mendel’s research. He recognized the pattern of 
Mendelian inheritance in human diseases and published his observation on alkaptonuria in 
1902 (Kennedy 2001). It sparked a new scientific quest to understand the biology of genetic 
information and content. Scientific progress revolutionized human genetics after the strenuous 
efforts in a time frame of 100 years. It started from the understanding of the basic rules of 
hereditary to the ultimate mapping of the complete sequence of the human genome (Kennedy 
2001). 
Human genetic diseases have traditionally been divided into ‘monogenic, simple and rare’ and 
‘multigenic, complex and common’ diseases (Bamshad et al. 2011). The elucidation of the 
underlying molecular cause of disease phenotypes is the major goal of medical genetics. 
Positional cloning was employed successfully to identify the mutated genes underlying human 
monogenic diseases (Botstein and Risch 2003). The development of DNA sequencing 
technologies and target enrichment strategies resulted in whole exome sequencing projects, 
which further expedited the identification of mutations in rare conditions (Ng et al. 2009). There 
are about 7,000 rare monogenic diseases and the molecular etiology is known only for >3,500 
(∼ 50%) (Boycott et al. 2013). Still, a large chunk of monogenic conditions with missing links 
is present in isolated and inbred populations across the world (Antonarakis and Beckmann 
2006). At present, the realistic aim is to find the candidate gene for every recessive disorder 
through global coordination and cooperation. This will not only provide enormous service to 
the families but also provide many novel entry points to understand the pathomechanisms of 
the diseases (Bamshad et al. 2011). 
3.1 Pakistani Population 
Pakistan lies on the postulated costal route with the evidence of settlers from 60,000 years ago 
(Mehdi et al. 1999). The country borders India in the east, Afghanistan in the north-west, Iran 
in the west, China in the north and the Arabian Sea in the south. Pakistan has world’s sixth 
largest population of 182 million people (WHO, 2013) who belong to at least 18 ethnic groups 
and speak >60 different languages (Grimes and Grimes 1993). In the different periods of 
history, Aryans, Macedonians, Arabs and Mongols settled after invasion and add to 
considerable ethnic diversity. The population is divided into Punjabi (44.15%), Pashtuns 
(15.42%), Serakis (10.53%), Kashmiri, Balti, Burushes and Hazaras in the north, and Balochis 
(3.57%), Brahuis, Makranis and Sindis (14.1%) in the south (Mehdi et al. 1999; Syed and 
  8 
Shehla 2011). After the 1947 partition, many ethnic groups migrated from India who are 
grouped as Muhajir (7.57%) (Syed and Shehla 2011). 
Ethno-cultural diversity had influenced the settlement and development of communities in the 
sub-continent (Ibbetson 1982). Consanguineous marriages are highly favoured due to different 
sociocultural, ethnic and geographical background. In Pakistan, 60% of marriage unions are 
consanguineous (Akram et al. 2008; Hussain 1999). Cousin marriages can lead to the 
multigenerational pedigrees with increase prevalence of recessive disorders, spontaneous 
abortion and other congenital malformations (Devi et al. 1987; Hussain 1999). Two 
independent studies found various congenital malformations in 14.79% and 40% cases where 
the parents were first or second cousins (Akram et al. 2008; Hafeez et al. 2007). Beta-
thalassemia is the most common inherited disorders with carrier frequency >5.6% and 9 million 
estimated carriers in Pakistan (Baig et al. 2012). The other most common inherited conditions 
are microcephaly and deafness. It is estimated that the primary microcephaly and profound 
bilateral hearing loss occur for 1 and 1.6 per 1000 births respectively (Ali 2010; Elahi et al. 
1998; Woods 2004). 
The high degree of consanguinity and different ethnicities constitute a unique resource to 
reveal the genetic basis of many traits (Hussain 1999; Mehdi et al. 1999). At present, many 
Pakistani families with multiple affected births having congenital inherited traits are left 
undiagnosed. Moreover, information and counselling regarding recurrence rates is never 
provided to the parents. In addition to counselling and symptomatic diagnosis, prenatal 
diagnosis is also a legal option in an Islamic society like Pakistan (Baig et al. 2012). In the 
current study, I focused on the molecular genetics of two neurodevelopmental disorders, 
primary microcephaly and microcephalic primordial dwarfism in the Pakistani population. The 
use of powerful tools in the field of modern human genetics provided us the best opportunity 
to identify the disease-causing variants in genes essential for embryonic development. 
3.2 Microcephaly 
Humans have large, convoluted and highly specialized brain structure which makes them a 
distinguished species on earth. The human brain associates with cognition, emotions and the 
power to orchestrate different thoughts always puzzled scientists and philosophers, and 
remained the most intriguing question for them (Genin et al. 2012; Hu et al. 2014). On the 
contrary, microcephaly is known to humans for a long time but it was only at the end of 19th 
century that attracted researchers to gain insights about the underlying pathomechanism of 
the disease (Opitz and Holt 1990). The term microcephaly is originated from Greek language 
and it is the combination of two words “Mikros” means small and “Kephalos” for head or skull. 
So, people born with smaller brain and head size than usual are microcephalic. 
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Microcephaly can be broadly divided on the basis of aetiology in to primary and secondary 
microcephaly. Primary microcephaly occurs at 32 weeks of gestation and has genetic 
background. Microcephaly can occur isolated, with no obvious abnormities, or it may be part 
of a syndrome of congenital anomalies, and therefore associated with other abnormities 
(Abuelo 2007; Passemard et al. 2013; Woods 2004). In secondary microcephaly, the child is 
born with normal head size but postnatal growth fails. Secondary microcephaly occurs through 
non genetic causes including environmental insults such as exposure to alcohol (foetal alcohol 
syndrome), toxins, foetal irradiation, placental insufficiency or congenital infections, (e.g. CMV, 
toxoplasmosis, HIV, rubella) and, rarely, maternal metabolic disorders e.g. maternal 
Phenylketonuria (PKU). 
3.2.1 Primary microcephaly 
Autosomal recessive primary microcephaly (MCPH, MIM 251200) or “microcephaly vera” is a 
genetically heterogeneous human brain disorder and a rare subgroup of congenital 
microcephaly (Tan et al. 2014a; Woods et al. 2005). It is defined as a reduced occipital frontal 
circumference (OFC) at birth that is less than four standard deviations (-4SD) below the age, 
sex and ethnicity (Woods et al. 2005).The affected individuals have varying degree of 
intellectual disability without other neurological findings. The presence of fits does not exclude 
the diagnosis. MCPH appears to be due to a failure of normal developmental processes rather 
than regression or degeneration in the neuronal tissue. In general, the architecture of the brain 
is not grossly affected (Thornton and Woods 2009; Woods et al. 2005) although in some cases 
structural defects in neural migration have been reported (Bond et al. 2002; Hussain et al. 
2013). 
The prevalence of microcephaly varies in different populations. The incidence of MCPH is 1 in 
a million in the Yorkshire region of Britain, 1/30,000 in Japan, 1/250,000 in Holland and 1/ 
2000,000 in Scotland (Komai et al. 1955; Tolmie et al. 1987; Van Den Bosch 1959).The 
prevalence of MCPH is higher in populations where consanguinity is widely practiced. The 
highest incidence of 1/10,000 is present in families originating from Northern Pakistan. The 
overall incidence is higher in South Asian and Arabic populations than Caucasian population 
(Woods et al. 2005). Genetic heterogeneity was expected in MCPH due to the broad spectrum 
of phenotypes (Cowie 1960). Majority of MCPH cases show normal height, chromosomal 
analysis, weight and MRI scan without gross structural abnormalities. The growing number of 
MCPH genes has increased the phenotypic spectrum like height reduction, chromosome 
condensation, lisencephaly, schizencephaly, polymicrogyria and hypoplasia of corpus 
callosum. Therefore, the diagnosis of MCPH no longer excludes the presence of these 
phenotypes (Woods et al. 2005). 
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Figure 3.1: MCPH patient from Pakistan (a) front view (b) side view showing the reduced head size 
and sloping forehead. 
3.2.1.1 Molecular genetics of primary microcephaly 
Primary microcephaly is a genetically heterogeneous disorder. So far, thirteen genes have 
been associated with primary microcephaly, eight of which have been published in the last six 
years as a result of rapid advancement of next generation sequencing and high–throughput 
deep sequencing (Hussain et al. 2013; Khan et al. 2014). All known genes for MCPH are 
summarized in Table 3.1. ASPM is the most common implicated gene in MCPH (Nicholas et 
al. 2009). Mutations in ASPM had been reported in many populations, including Pakistan, Iran, 
India, Middle Eastern, Caucasian, Turkey, African, African American, Hispanic (Bond et al. 
2003; Darvish et al. 2010; Kumar et al. 2004; Nicholas et al. 2009; Tan et al. 2014a). The 
majority of the MCPH proteins are associated with centrosome or spindle pole and are the part 
of many biological processes from centrosome maturation, centriole biogenesis, spindle 
position, to DNA repair (Thornton and Woods 2009). In the following lines, I will briefly discuss 
the genes where I found mutations in the current study. 
3.2.1.1.1 Microcephalin (MCPH1) 
The first molecular defect was identified in MCPH1 in families of Pakistani origin (Jackson et 
al. 2002). Microcephalin, the MCPH1 product, consists of 835 amino acids with three BRCA1-
carboxy terminal domains (BRCT domains) (Jackson et al. 2002). Microcephalin has been 
shown to play a variety of roles in cell cycle regulation of neuronal progenitors and DNA 
damage response pathways. It has been demonstrated that microcephalin co-localises with 
DNA damage checkpoint 1 (MDC1) protein and H2AX in foci induced by ionizing radiation 
which are required for the recruitment of many downstream DNA damage response proteins 
(Lin et al. 2005; Xu et al. 2004). The phenotypic spectrum of MCPH1 mutations is not only 
limited to primary microcephaly but several studies have been conducted to address the 
genetic, epigenetic and functional role of MCPH1 in various forms of cancer (Venkatesh and 
Suresh 2014). 
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3.2.1.1.2 WD repeat-containing protein 62 ( WDR62) 
WDR62 (MCPH2; OMIM 604317) is the second most common genetic cause of primary 
microcephaly. The WDR62 consists of 32 exons and encodes a 1523 amino acids long protein. 
Mutations in WDR62 account for 10% of the MCPH cases (Nicholas et al. 2010; Thornton and 
Woods 2009). Various mutations in WDR62 can be associated with additional cortical 
abnormalities including lissencephaly, polymicrogyria and heterotopia. WDR62 is associated 
with the mitotic spindle poles and is essential for the proliferation of neural progenitor cells 
(NPCs) (Bilguvar et al. 2010; Nicholas et al. 2010; Yu et al. 2010). Depletion experiments in 
mice showed spindle instability, mitotic arrest and cell death for NPCs and displayed the 
phenotypes of primordial dwarfism and microcephaly (Chen et al. 2014). 
 3.2.1.1.3 Cyclin-dependent kinase 5 regulatory subunit-associated protein 2 
(CDK5RAP2) 
CDK5RAP2 encodes a 1893 amino acid, 215 kDa, pericentriolar material (PCM) protein that 
is important for the recruitment of other PCM components. It recruits the γ-tubulin ring complex 
(the microtubule nucleator) to the centrosome through its N-terminus (Bond et al. 2005; Fong 
et al. 2008) and interacts with Pericentrin through C-terminus (Wang et al. 2010). It also plays 
a pivotal role in centrosome maturation (Dobbelaere et al. 2008) and centrosome cohesion 
(Graser et al. 2007) and regulates the assembly of microtubules (Fong et al. 2008). Mutations 
in human CDK5RAP2 caused MCPH phenotypes (MCPH3; OMIM 604804). The patients 
showed reduced brain size without other cortical abnormalities (Bond et al. 2005). It has been 
shown that Cdk5rap2 is highly expressed in the mouse embryonic brain and is essential for 
the survival of cortical progenitors and their proliferation. Its depletion leads to a reduction in 
the proportion of apical progenitor cells. There was also an increased level of apoptosis 
observed in Cdk5rap2 deficient mouse embryos (Buchman et al. 2010; Lizarraga et al. 2010a). 
3.2.1.1.4 Abnormal spindle-like microcephaly- associated protein (ASPM) 
ASPM, the human orthologue of Drosophila melanogaster abnormal spindle gene (asp), is the 
most frequently mutated gene in >50% cases with MCPH phenotypes (Thornton and Woods 
2009). It is involved in the organization and binding of microtubules at spindle poles and 
localises to the central spindle during meiosis and mitosis (Riparbelli et al. 2002; Ripoll et al. 
1985). It is highly expressed during the cerebral cortical neurogenesis especially in the 
ventricular zone in the mouse brain (Bond et al. 2002). The cortical size is then determined by 
the innate property of neural progenitor cells to switch from symmetric proliferation to 
asymmetric. In the absence of ASPM, cleavage plane is changed from the normal ventricular 
  12 
orientation and result in a premature switch to asymmetric division of NE cells (Fish et al. 
2006). The aspm mutant mice exhibit microcephaly and loss of germ cells which were rescued 
with the human ASPM transgene (Pulvers et al. 2010). 
Table 3.1: List of known MCPH genes. 
Gene Disease 
locus 
Cytogenetic 
location  
OMIM # Reported in 
Population 
Protein 
localization 
 
MCPH1 MCPH1 8p23 251200 Pakistani centrosome 
and nucleas 
 
WDR62 MCPH2 19q13.12-q13.2 604317 Pakistani mitotic 
spindle pole 
 
CDK5RAP2 MCPH3 9q33.2 604804 Pakistani centrosome 
 
CASC5 MCPH4 15q14-15.1 604321 Moroccan kinetochore 
 
ASPM MCPH5 1q31.3 608716 Pakistani mitotic 
spindle and  
mid body 
CENPJ MCPH6 13q12.12 608393 Brazilin centrosome 
 
STIL MCPH7 1p33 612703 Indian centrosome 
 
CEP135 MCPH8 4p14-q12 614673 Pakistani centrosome 
 
CEP152 MCPH9 15q21.1 614852 Pakistani centrosome 
 
ZNF335 MCPH10 20q13.12 615095 Israeli nucleus 
 
PHC1 MCPH11 12p13.31 615414 Saudi 
Arabian 
nucleus 
CDK6 MCPH12 7q21.2 616080 Pakistani centrosome 
 
SASS6 MCPH14 1p21.2 616402 Pakistani centrosome 
CENPE (MCPH13, MIM 117143) was omitted from the above list because the gene is reported with 
different phenotypes. 
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3.2.2 Microcephalic primordial dwarfism (MPD) 
Primordial dwarfism is a group of monogenic disorders in which growth of the individuals is 
restricted from the prenatal stage onward and is continuously reduced after birth. These 
individuals were described as “miniature construction with approximately normal 
anthropometric proportion” or were the centre of attraction in sideshows and circuses in the 
19th and 20th century (Hall 2013; McKusick 1955). When the individuals have a reduced head 
size in proportion to or smaller than the body size, the condition constitutes a separate 
distinguished group, microcephalic primordial dwarfism (Fig 3.2-A) (Klingseisen and Jackson 
2011). This group encompasses several subtypes of human genetic disorders including Seckel 
syndrome (Majewski et al. 1982; Seckel 1960), Microcephalic Osteodysplastic Primordial 
Dwarfism (MOPD), type I and II (Hall et al. 2004; Majewski et al. 1982) and Meier-Gorlin 
Syndrome (MGS) (Gorlin et al. 1975). There is a substantial number of microcephalic 
primordial dwarfism cases which do not fit into the current diagnostic scheme. However, all 
these disorders have autosomal recessive segregation and the cardinal features include 
intrauterine growth restriction, proportionate dwarfism, severe microcephaly and varying 
degrees of intellectual impairment (Hall et al. 2004; Klingseisen and Jackson 2011). 
Genes that are described for microcephalic primordial dwarfism are listed in Table 2. PLK4 is 
the new gene identified in a consanguineous Pakistani family in this study. This list includes 
some of the genes which are also involved in isolated primary microcephaly cases. To date, 
the underlying cause for these genetic overlaps is unknown. This is a very intriguing question 
that will need to be addressed in the future. 
  
Figure 3.2: Scaling of height and head size to normal average adult: (A) depicts microcephalic 
primordial dwarfism. (B) Normal adult individual. (C) Primordial dwarfism. Adopted from (Klingseisen 
and Jackson 2011). 
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 Table 3. 2: Summary of the identified genes in MPD 
Type of  MPD Genes 
involved 
Disease 
locus 
OMIM* Cytogenetic 
location  
Protein localization 
 
 
 
 
 
 
 
 
 
 
 
Seckel 
syndrome 
ATR  
 
SCKL1 210600 
 
3q23 centrosome and nucleus 
RBBP8 SCKL2 606744 
 
18q11.2 nucleus 
ATRIP  
 
   -  3p21.31 nucleus 
CENPJ 
 
SCKL4 613676 
 
13q12.2 
 
centrosome 
CEP152 
 
SCKL5 613823 
 
15q21.1 
 
centrosome 
CEP63 
 
SCKL6 614728 
 
3q22.2 centrosome 
NIN 
 
SCKL7 614851 
 
14q22.1 centrosome 
DNA2 SCKL8 615807 10q21.3 nucleus 
MOPD I RNU4ATAC      - 210710 2q14.2    component of the 
spliceosome 
 
MOPD II 
PCNT MOPD2 210720 21q22.3 centrosome 
CENPE     - 616051  4q24 kinetochore 
 
 
 
 
 
 
Meier-Gorlin 
Syndrome 
ORC1 MGORS1 224690 1p32.3 centrosome and nucleus 
ORC4 MGORS2 
 
613800 2q22.3-q23.1 nucleus 
ORC6 MGORS3 
 
613803 16q11.2  kinetochore 
CDT1 MGORS4 
 
613804 16q24.3 kinetochore 
CDC6 MGORS5 
 
613805 17q21.2 nuclear and cytoplasmic 
 
Uncategorized 
types 
IGF1 - 608747 12q23.2 nucleus 
LIG4 - 606593 13q33.3 nucleus 
CRIPT - 615789 2p21 nucleus and cytoplasm 
PLK4 - 616171 4q28.2 centrosome 
XRCC4  -     - 5q14.2 nucleus and cell 
cytoplasm 
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3.2.2.1 Plk4 (Polo- like kinase 4) 
Polo-like kinases (Plks) are a family of serine-threonine protein kinases. The founding member 
(Plk1) was first identified in Drosophila where a mutant exhibited defective spindle pole 
behaviour (Sunkel and Glover 1988). The PLKs family consists of five members: Plk1, 
Plk2/Snk, Plk3/Fnk/Prk, Plk4/Sak and Plk5 (de Carcer et al. 2011; Sillibourne and Bornens 
2010). PLKs has miscellaneous roles and is critical for many cellular processes including 
regulation of mitosis, chromosome segregation, cytokinesis, spindle pole formation, and cell 
cycle checkpoints in response to DNA damage (de Carcer et al. 2011). Plk4 has no direct 
homologue in C. elegans but zyg-1 has been proposed as the functional complement due to 
its essential role in centriole duplication (O'Connell et al. 2001). All members of the Plks family 
have a special modular architecture that connects a C-terminal structure (Polo box domain) to 
the N-terminal kinase domain. Plk1-3 contains two Polo box domains at their carboxyl tail 
domain, while Plk4 has one (Sillibourne and Bornens 2010). However, Plk4 possesses a 
unique central region called cryptic polo box (CPB) domain (cassette of PB1-PB2) which make 
Plk4 a distinguished memeber in the Plks family (Fig 3.3). Plks have 3 PEST sequences which 
are known to have role in kinase stability (Sillibourne and Bornens 2010). The C-terminal Polo 
box domain, the PB3 domain, exists as homodimer, composed of twisted antiparallel ß sheets 
and a C-terminal helix (Jana et al. 2012) (Fig 3.3-D). The precise role of PB3 is largely 
unknown. It was thought that it confers the ability to homodimerize but recent studies 
demonstrated that PB3 is not necessary for Plk4 dimerization (Klebba et al. 2015a; Leung et 
al. 2002). Loss of the PB3 domain causes a reduced centriole targetting. In a recent study a 
novel role was assigned to the PB3 domain where it was shown that autoinhibition of Plk4 is 
relieved through the PB3 domain. Further, the kinase activity was impaired in a Plk4-∆PB3 
protein (Klebba et al. 2015a). Plk4 dimerizes through the CPB. It brings together a degron motif 
located near the kinase domain, which then recruits the SCF Slimb/β-TrCP ubiquitin ligase, resulting 
in its ubiquitination and proteasomal degradation (Klebba et al. 2013). Morever, the CPB was 
shown to interact with the N-terminus of Asl/CEP152 and drive centriole biogenesis but recent 
studies revealed that the C-terminus of Asl binds to the CBP of Plk4 to initiate centriole 
duplication while the N-teminus of Asl promotes Plk4 homodimerization (Klebba et al. 2015b). 
Loss of Plk4 in mice (Plk4-/-) leads to an arrest of the embryo at E7.5 and is embryonically 
lethal with marked increase in mitotic and apoptotic cells, indicating that Plk4 is essential for 
embryonic development (Hudson et al. 2001). Plk4+/- mice grew normally but gradually 
developed tumors in adulthood, especially in liver and lung tissues. In addition, Plk4+/- MEFs 
displayed centrosome amplification, reduced cell growth and defective spindle formation (Ko 
et al. 2005). In support of these findings, another study found multinucleation, centrosome 
amplification and tetraploidy in early passages of Plk4-/+ derived mouse embryonic fibroblasts 
  16 
(MEF) and proposed cytokinesis failure as underlying mechanism (Rosario et al. 2010). On 
contrary, a recent study showed no centrosome amplification and gross chromosomal 
abnormalities in Plk4+/- MEF cells and further indicated that Plk4 has no direct role in 
cytokinesis but rather leads to centriole loss and spindle defects (Holland et al. 2012a). Plk4 is 
a conserved master regulator of centriole biogenesis, and its overexpression leads to centriole 
amplification and denovo centriole assembly (Avidor-Reiss and Gopalakrishnan 2013; 
Bettencourt-Dias et al. 2005). Centrosome amplification effects were investigated in the 
developing mouse brain and serendipitously a microcephaly phenotype was found (Marthiens 
et al. 2013). However, Plk4 is autoregulated and promotes its own destruction to limit centriole 
duplication once per cell cycle (Holland et al. 2012b). Depletion of SAK/Plk4 in Drosophila 
causes centriole loss, mitotic abnormalities, and defective spermatides without axonemes 
structure (Bettencourt-Dias et al. 2005). In our study we found centriole loss, monoploar 
spindles and delayed mitotic progression in PLK4 deficient cells from patients with 
microcephalic primordial dwarfism, the first human phenotype associated with PLK4 (Martin et 
al. 2014). 
                
Figure 3.3: Organization and structure of PLKs: (A) Domain organization of human and Drosophila 
PLK4 and human PLK1. (B) Quaternary structures of the polo box domain in human PLK1. (C) 
Quaternary structures of the cryptic polo box in Drosophila PLK4 (D) PLK4 domain-swapped PB3 dimer. 
Adopted from (Jana et al. 2012). 
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3.3 The centrosome 
The vertebrate centrosome is composed of two orthogonally arranged centrioles that are 
embedded in a pericentriolar material (PCM), which is a matrix that surrounds the centrioles 
and is enriched in different proteins required for centrosome associated functions. Centrioles 
are barrel-shaped structures composed of nine triplets of microtubules with dimensions of 0.5 
µm length and 0.2 µm in diameter (Fig 3.4). The centrioles also contain highly stable distal and 
sub distal appendages (Bettencourt-Dias 2013; Doxsey 2001). The PCM is highly dynamic and 
contains a high proportion of coiled-coiled proteins which provides docking sites for various 
proteins, particularly members of the γ-tubulin ring complex (γTuRC) (Doxsey 2001). 
Centrioles are the major players which determine most properties of the centrosome. The 
centrosome has several functions that act primarily around cell cycle regulation and 
microtubule organization. Besides microtubule nucleation, it facilitates mitotic spindle 
assembly, chromosome segregation fidelity, and spindle orientation to the cell cortex in the 
developing embryo. It lays a patch for the assembly of primary cilia and is involved in signal 
transduction. In additional, it is also engaged in cell migration, vesicle trafficking, and cell 
polarity (Bettencourt-Dias 2013; Bornens 2012; Chavali et al. 2014). Centrosomes are not 
essential in all organisms and there are many exceptions existing in the eukaryotic tree. 
Centrosomes are absent in many species such as fungi, seed plants, and in many classes of 
protists that are thought to have lost the ability to encode proteins essential for centrosome 
assembly (Bettencourt-Dias 2013; Carvalho-Santos et al. 2011). 
    
Figure 3.4: Structure of the centrosome. Schematic of the centrosome showing a centrosome 
consisting of the centrioles and the surrounding PCM. Adopted from (Doxsey 2001). 
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Despite the lack of centrosomes these organisms have a well-organized microtubule 
cytoskeleton system. There are some classes of animals like Planaria which assemble cilia 
through centrioles but have no centrosome. In mammals, the female oocyte and the mouse 
embryo lacks centrioles until the 64 cells stage. Along these limitations of the centrosome, it is 
quite essential in other organisms for  tissue development (Bettencourt-Dias 2013). 
3.3.1 Centrosome duplication cycle 
The centrosome plays an important role in the cell cycle, having a dominant role in guiding 
spindle formation. The centrosome number is regulated in a controlled manner during the cell 
cycle, and division occurs once per cell cycle in a semi-conservative manner (Holland et al. 
2010). The centrosome cycle is completed after a sequence of many key events (Fig 3.5). GI 
phase cells possess one centrosome that contains one mature centrioles called the mother 
centriole, generated at least two cycles before, and the other is the daughter or immature 
centriole, generated in the previous cell cycle (Azimzadeh and Bornens 2007). 
 
 
Figure 3.5: Centrosome duplication cycle: Schematic diagram showing the different stages of the 
centrosome duplication cycle.  Mother centrioles are shown in dark gray and daughter centriole in 
blue-green. This image is taken from (Afonso et al. 2007). 
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The mother centriole is distinguished by the presence of appendages at the distal end. At the 
early G1 phase before completion of cytokinesis, the two centrioles disengage and the new 
procentriole assembles at a perpendicular angle next to each parental centriole in S phase. As 
the cell progresses through S and G2 phases, procentrioles elongate and attain their final 
length at G2. At the G2-M phase transition, the two centrosomes separate, start to instruct the 
formation of spindle poles and gradually move to the opposite poles. At late cell division, the 
connection between mother and procentriole are removed and disengage both centrioles. The 
daughter centrioles mature and secure distal and sub distal appendages in the following cycles 
(Azimzadeh and Bornens 2007; Holland et al. 2010). 
3.4 Centrosome and primary microcephaly proteins 
Centrosome dysfunction has been linked with many human diseases such as defects in brain 
development, cancer and ciliopathies. MCPH has been found the bona fide model genetic 
disorder for centrosome and associated proteins. In general, microcephaly is the prominent 
feature of many developmental brain disorders. The genes afflicted in MCPH can be classified 
into three categories according to their function; (i) centriole duplication; (ii) centrosome 
maturation and spindle pole formation; (iii) other cell cycle associated functions (Table 3.1; Fig 
3.6). Five MCPH proteins (CENPJ, STIL, CEP135, CEP152 and HsSAS-6) play important roles 
in centriole duplication. The formation of new centrioles requires core centrosomal 
components, including PLK4, STIL/Ana2/SAS-5, CPAP/CENPJ/SAS-4, CEP135/Bld10 and 
CEP152/Asl (Bettencourt-Dias et al. 2011; Chavali et al. 2014). Interestingly, four of these 
carry MCPH-linked mutations, and PLK4 is now established as the cause of MPD through the 
current study (Martin et al. 2014), and by an independent study (Shaheen et al. 2014a). 
CEP152 acts as scaffold and interacts with CEP192 to recruit polo-like kinase 4 (PLK4) to 
trigger centriole biogenesis. This is followed by the recruitment of HsSAS-6 (MCPH12), STIL 
(MCPH7) and then finally CENPJ (MCPH6) protein. CENPJ (MCPH6) is the key button of the 
MCPH protein network, because it binds STIL, CEP152 and CEP135, albeit most likely not 
concurrently (Bettencourt-Dias et al. 2011; Chavali et al. 2014). 
CDK5RAP2 is essential for centrosome maturation, centriole cohesion, and shackles the 
centrosome to the mitotic spindle poles. In the absence of CDK5RAP2, centrioles detached 
from the spindle poles (Barr et al. 2010). The orthologue of ASPM has been shown to be crucial 
for mouse and Drosophila. On depletion, centrosomes were detached from the spindles (Fish 
et al. 2006; Gonzalez et al. 1990). WDR62 and CDK6 proteins are also associated with spindle 
poles during mitosis, and mimic the localization of ASPM, CENPJ and CEP152 have also role 
in centrosome maturation (Bettencourt-Dias et al. 2011; Hussain et al. 2013). 
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The remaining four MCPH proteins show no clear functional overlap. MCPH1 is a nuclear and 
centrosomal protein which is involved in the control of the cell cycle, DNA damage and repair 
(Cox et al. 2006). CASC5 is a kinetochore scaffold protein and required for the correct 
attachment of centromeres to the mitotic apparatus, and is necessary for spindle-assembly 
checkpoint (SAC) signaling (Genin et al. 2012). The ZNF335 protein is localized in the nucleus 
and plays a role in chromatin remodeling. It binds to the promoter region of transcription factor 
REST/NRSF, which has a crucial role in neurogenesis and neural differentiation (Yang et al. 
2012). PHC1, a member of the polycomb group, localizes to the nucleus and promotes the 
ubiquitination of histone H2A. It regulates the levels of GEMININ, a protein which is involved 
in cell cycle regulation and partly localizes to the centrosome (Barbelanne and Tsang 2014; 
Khan et al. 2014). 
3.5 Short commentary on cellular pathways in microcephalic 
primordial dwarfism (MPD) 
The molecular genetics of primary microcephaly and primordial dwarfism has highlighted the 
phenotypic and genetic overlap. At least ≥ 21 genes have been implicated in microcephalic 
primordial dwarfism. The genetic aberrations in these genes are not only associated with 
reduced brain size but also cause substantial growth failure. These genes encode proteins that 
are involved in cell cycle regulation and cell divisions. Most of the genes mutated in primordial 
dwarfism activate proteins which are part of the ataxia telangiectasia mutated (ATR) signaling 
pathway (Chavali et al. 2014; Klingseisen and Jackson 2011). ATR and its main substrate 
CHK1 coordinate the response to DNA damage and replicative stress. ATR is essential from 
S to M phase progression or for stabilizing of stalled replication forks (Alderton et al. 2004; 
Chavali et al. 2014). Proteins (ORC1, ORC4, ORC6, CDT1 and CDC6) associated with the 
replicative complex formation, and origin activation showed alterations in cell-cycle kinetics 
through replicative stress in Meier-Gorlin syndrome (Bicknell et al. 2011; Bleichert et al. 2013). 
The accumulation of replicative stress disrupts development and tissue homoeostasis. 
Mutations in ATR, ATRRIP, CtIP genes associated with Seckel syndrome lead to deficient ATR 
signaling pathways (Ogi et al. 2012; Qvist et al. 2011). Similarly, core centrosomal protein 
PCNT mutant cells exhibit impaired ATR signaling with defective G2/M checkpoint (Tibelius et 
al. 2009). Interestingly, the MCPH gene CEP152, also appears in the maintenance of genomic 
integrity and caused Seckel syndrome. In CEP152 deficient fibroblasts CHK1 function is 
normal and activation of the Ataxia telengiectasia-mutated (ATM) singaling pathway occurs 
(Kalay et al. 2011). The accumulation of replicative stress and the premature checkpoint arrest 
in ATM or ATR signaling pathways create antiproliferative effects that impede cellular growth 
during development (Chavali et al. 2014; Klingseisen and Jackson 2011). Centrosome 
amplification and aneuploidy is another cause that can affect the cellular growth as 
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demonstrated in the patient cells that were deficient in PCNT, CEP152, ORC1 and CPAP 
proteins (Alderton et al. 2004; Chavali et al. 2014; Hossain and Stillman 2012; Kalay et al. 
2011). Cells with excess centrosomes should cluster them in two poles (Quintyne et al. 2005). 
Otherwise cells with centrosome amplification undergo multipolar cytokinesis and cell death. 
In spite of this crucial role, centrosome clustering leads to a delay in mitosis and genomic 
instability as observed in CPAP-Seckel mouse cells and CEP152-Seckel lymphocytes (Kalay 
et al. 2011; McIntyre et al. 2012). It seems that genes associated with microecphalic primordial 
dwarfism prevent centrosomal duplication. This notion is further supported by the finding that 
ORCI suppresses CDK2-cyclin E dependent centriole duplication (Hossain and Stillman 2012). 
Lastly, recent studies indicated that cilia dysfunction also contributes to the pathomechanism 
of MPD. The depletion of ORC1 in wild type cells, and ORC1-deficient patient primary 
fibroblasts leads to defective cilia formation and impaired sonic hedgehog signaling (Shh). The 
Shh pathway appears to have an important role in embryogenesis (Stiff et al. 2013). 
 
 
Figure 3.6: Schematic of the vertebrate centrosome and the mitotic spindle. The location of MCPH and 
MPD associated proteins are shown. MCPH protein are listed in red, MPD proteins in blue and proteins 
involved in both disorders are shown in bluish color. This image is modified from (Chavali et al. 2014). 
3.6 Corticogenesis and primary microcephaly 
Humans have more than 100 billion nerve cells in their brain (Stiles and Jernigan 2010). 
Scientists have now gained major insights to understand the critical components of normal 
brain development and functions. Primary microcephaly has been identified as the disease of 
neurogenic mitosis which results in a reduction of the cell number in the developing human 
brain. A unifying theme stemming from the molecular genetic studies is the role of the 
centrosome and its association with the neural progenitors (Cox et al. 2006; Hu et al. 2014). 
The association of MCPH proteins with the centrosome and cell cycle was already discussed 
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under the heading 3.4. In the next section, current concepts concerning primary microcephaly 
are reviewed. 
A. Symmetric and asymmetric cell division  
In human, the neural tube is formed during the third week of gestation. The neural progenitor 
cells line the center of the neural tube. When the brain becomes larger, the lumen and neural 
progenitor cells form the ventricular zone (VZ). At the end of gastrulation, neural progenitor 
cells undergo symmetrical division and two identical neural progenitor cells at each division 
are generated and hence they exponentially enlarge the progenitor populations (Stiles and 
Jernigan 2010). At E42, the mode of cell division switches from symmetrical to asymmetrical, 
generating one progenitor and a neuron that leaves the ventricular zone and divides no further. 
This results in increasing numbers of neurons and cortical thickness. The new progenitor cells 
remain in the proliferative zone and continue to divide. In human, cortical neurogenesis is 
completed by approximately at E108 (Clancy et al. 2001; Stiles and Jernigan 2010; Wodarz 
and Huttner 2003). 
The differentiated neurons migrate radially from the proliferative zones to the developing 
neocortex. In earliest migration neurons adopt a somal translocation mode but as development 
proceeds, the neurons use radial glial cells for migration. The migration ultimately leads to the 
formation of the 6-layered cortex. This occurs with the earlier neurons constituting the deepest 
layer and the following neurons forming the outer layers in an inside-out fashion (Stiles and 
Jernigan 2010).The balance between progenitor cell expansion and differentiation is essential 
for the precise numbers of neurons and brain size (Chenn and Walsh 2002; Noctor et al. 2004). 
Spindle-pole positioning relative to the apical–basal axis of neuroepithelial cells determines 
the overall orientation of cleavage. Vertical cleavage leads to two identical progenitor daughter 
cells while the outcome of horizontal cleavage are an apical and a basal daughter cell (Gotz 
and Huttner 2005). 
Disturbance of these divisions affect the neural progenitor pool. Genes that are mutated in 
MCPH encode proteins that regulate several key functions and are expressed in embryonic 
neurogenesis. Most of these proteins are localized at the centrosome and the spindle poles 
(Fig 3.6). So it is speculated that these MCPH proteins influence the orientation of the mitotic 
spindle and the mode of cell division in stem cell division (Fig 3.7). As a consequence of the 
premature shift from symmetric to asymmetric cell divisions, the progenitor cell pool is depleted 
and thus a reduced number of neurons results in the congenital condition of primary 
microcephaly (Cox et al. 2006). 
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Figure 3.7: Schematic representation for the neurogenesis in the rodent brain. The neural progenitor 
cells (NEP) expand through symmetric division to exponentially enlarge the progenitor population but 
after the onset of neurogenesis, NEPs give rise to the radial glial (RG) cells which divide by symmetric 
division and asymmetric division. They are lying in the ventricular zone. The progenitor cells display a 
vertical cleavage plane to the apical surface in case of symmetric division while in case of asymmetric 
division, they display oblique or horizontal cleavage planes. This image is taken from (Chavali et al. 
2014). 
B. Apoptosis  
In addition to the cell fate choice, cell death and premature cell cycle exit during neurogenesis 
has been proposed to contribute to the pathomechanism of MCPH. Microcephalin mediated 
DNA-damage response through ATM or ATR signaling pathways caused reduced neuron 
progenitor proliferation by inducing apoptosis. In recent studies, centrosome defects and errors 
in chromosome segregation are observed in microcephaly mouse models which lead to 
aneuploidy, mitotic arrest, and ultimately apoptosis (Gruber et al. 2011; Lizarraga et al. 2010b). 
The overexpression of PLK4 in the mouse brain did not significantly disturb spindle orientation 
but rather promoted p53 dependent apoptosis, seemingly as the result of aneuploidy 
(Marthiens et al. 2013). 
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4. Aims and objectives of the thesis 
The main focus of my PhD thesis is to identify genetic variants that cause two types of inherited 
neurodevelopmental disorders: primary microcephaly, a typically lethal condition characterized 
by small brains, and microcephalic primordial dwarfism (MPD), i.e. when primary microcephaly 
is combined with a global growth failure. 
Individuals suffering from MPD are usually described as the smallest people in the world. 
Mostly, the genetic components of both disorders are involved in the regulation of the cell cycle 
or are part of the core cellular machinery. The highly consanguineous Pakistani population is 
a goldmine for genetic studies to identify the defects underlying the diseases. The identification 
of new genes involved will improve diagnostics and management of these rare genetic 
disorders. It can increase our understanding of how the body regulates brain and cellular 
growth during embryonic development. The specific aims of this thesis are: 
1. To analyze Pakistani consanguineous families segregating primary microcephaly and 
microcephalic primordial dwarfism. 
2. To screen for mutations in previously reported genes to broaden our knowledge on the 
mutational spectra 
3. To identify causative variants in novel genes associated with MCPH and MPD 
4. To understand the basic cellular mechanisms and their role in the development of 
pathological phenotypes 
4. To uncover the functional consequences of the identified causative variants and the role of 
the newly associated genes in the etiology of the corresponding disease. 
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5. Materials and Methods 
5.1 Families studied 
For the study presented here, twenty nine consanguineous families of autosomal recessive 
primary microcephaly (MCPH) were recruited from the Khyber Pakhtunkhwa, Sindh and 
Punjab provinces of Pakistan. Among these families, there were 113 MCPH affected members 
with a male to female ratio of 63:50 respectively. This cohort had families from different 
ethnicities and geographical origin of Pakistan. The number of affected members in each family 
varied from 2 to 13. In addition, a family segregating inherited microcephalic primordial 
dwarfism with seven affected individuals was ascertained from Khyber Pakhtunkhwa, province 
of Pakistan. Informed consent was obtained from families who agreed to participate in this 
study. All families demonstrated the autosomal recessive mode of inheritance. Clinical 
examination was performed meticulously with careful measurement of head circumference, a 
simple method used to asses gross brain size (Woods et al. 2005). All affected individual 
displayed reduced head circumference (-5 SD to -13 SD) whereas their parents were normal. 
There was no indication of growth retardation or other neurological deficits except seizure was 
reported in some patients which are no longer excluded from the MCPH diagnostic criteria 
(Woods et al. 2005). The degree of intellectual disability varied from mild to severe or even 
profound and it differed among patients within the families. In most MCPH patients 
communication barrier was obvious while some patients had the ability to speak short 
sentences and basic knowledge of native language. Cognitive deficits were evident in most 
cases while some patients had delayed motor skills. The phenotypes of all twenty nine 
congenital MCPH families are documented by photos (Fig 5.1). 
The patients in MCP68 were diagnosed as having microcephalic primordial dwarfism in 
accordance with the classification of primary microcephaly-seckel spectrum disorders (Verloes 
et al. 1993). The general criteria set for such syndromes are the prenatal onset of proportionate 
dwarfism, marked microcephaly, intellectual disability and autosomal recessive segregation. 
5.2 Pedigree construction and analysis 
To make genetic conjecture, extensive pedigrees were drawn for each family using standard 
methods. The inheritance pattern in the families was inferred by observing the mode of 
segregation. The genealogical relationships for all affected individuals were established 
through personal interviews of the elderly of the family. The males were symbolized by squares 
and females by circles. The phenotypically normal individuals were indicated with unfilled 
symbols while the affected individuals were depicated by filled symbols. A number enclosed 
within a symbol indicates the number of sibs, male or females, as the case may be. Deceased 
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individuals were presented as line across the symbols. A horizontal line connecting a circle 
and square is a marriage line while a double horizontal line shows consanguinity. An arrow 
pointing at a particular affected individual is the starting point for construction of the pedigree 
(general proband, propositus for male and proposita for female). Pedigrees were constructed 
using HaploPainter v.1.043 (Thiele and Nürnberg 2005). All the family data were arranged in 
the form of pedigrees, the mode of inheritance of all studied families was ascertained as 
autosomal recessive. 
          
Figure 5.1: Clinical features of affected individuals of primary microcephaly families. 
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5.3 Blood sampling 
Peripheral blood samples were taken from all available affected individuals, parents and 
normal members of the family with informed consent. Blood was collected in 10 ml BD 
vacutainer® (BD-Plymouth, UK) containing EDTA as anticoagulant. These blood samples 
were stored at 4 oC for short term or at -80 oC for longer periods until DNA extraction. 
5.4 DNA extraction 
Genomic DNA was extracted with phenol- chloroform isoamyl alcohol, a common protocol for 
isolation of DNA from blood. 0.75 ml of blood was taken in a 1.5 ml sterile microcentrifuge tube 
with equal volume of 0.75 ml of solution A and kept at room temperature for 10-15 minutes 
after mixing the contents. The tubes were then centrifuged for 1 minute at 13,000 rpm and 
discarded the supernatant. The pellet was resuspended in 400 μl of solution A and repeated 
centrifugation and discarding the supernatant. Nuclear pellet was resuspended in 400 µl of 
solution B, 25 μl of 10% SDS and 8 µl of proteinase K and incubated at 65 oC for three hours 
in water bath or at 37 oC for overnight. After this step, 0.5 ml of freshly prepared solution C and 
D was added into samples, mixed and centrifuged for 10 minutes at 13,000 rpm. The top 
(aqueous) phase was collected carefully in a new 1.5 ml microcentrifuge tube and added equal 
volume of solution D. Centrifugation was then performed at 13,000 rpm for 10 minutes. The 
aqueous phase was transferred to a new sterile tube and added 55 µl of 3 M sodium acetate 
(pH 6) and equal volume of isopropanol. Tubes were then inverted several times to precipitate 
DNA. DNA was incubated with 350 µl of 70% ethanol (stored at -20 oC) and centrifuged at 
13,000 rpm for 10 minutes. Ethanol was drawing off from side without disturbing DNA pellet. 
DNA was dried and dissolved in appropriate amount of buffer FG3 (Qiagen) or ultrapure water. 
Composition of solutions 
Solution A (pH 7.5) 
0.32 M Sucrose   54.72 g 
10 mM Tris-HCl (pH 7.5)  5 ml (1 M)  
5 mM MgCl2    2.5 ml (1 M) 
First, the aforementioned chemicals were dissolved in 400 ml of distilled water and adjusted 
to pH 7.5. The volume was made up to 495 ml with distilled water and autoclaved. After 
autoclaving, the bottle was allowed to cool at room temperature. The volume of solution was 
raised to 500 ml (final volume) by adding 5 ml of Triton X-100 (1% v/v) and was autoclaved 
before use.  
Solution B 
10 mM Tris-HCl (pH 7.5)  5 ml 
400 mM NaCl    40 ml 
2 mM EDTA (pH 8.0)   2 ml 
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The solution was brought to 500 ml (final volume) and autoclaved. 
Solution C (saturated phenol pH 8.0) 
100 ml Phenol (Sigma-Aldrich) was heated to 68 oC in a water bath. Then it was mixed with 
100 ml of 0.5 M Tris-HCl (pH 8.0) and 100 mg of hydroxyquiniline (0.1%). The mixture was 
stirred for 15-20 minutes on a magnetic stirrer. The aqueous upper phase was discarded and 
added 0.1 M Tris-HCl (pH 8.0) of equal volume to the lower phase. The solution was stirred 
for 15 minutes. The upper phase was removed again and repeated it several times until the 
pH of phenol reached to 7.8. The pH of the phenol was measured within the upper phase. 
Next, 10 ml of Tris-HCl was added that had 200 µl of β-mercaptoethanol. The solution was 
stored for 1 month at 4 oC. 
Solution D 
Chloroform   24 volume 
Isoamy alcohol  01 volume 
5.4.1 DNA quantification 
DNA integrity was assessed through 1% agarose gel and quantified through NanoDrop TM 
1000 Spectrophotometer (Wilmington, USA) for further experiments. 1.5 μl of well mixed DNA 
dilutions was directly placed onto the ND-1000 Spectrophotometer. For each sample, DNA 
light absorbance at 260 nm and 280 nm was measured three times. The DNA purity and 
concentration were calculated directly by the provided software. 
5.4.2 Polymerase chain reaction (PCR) and gel electrophoresis 
Polymerase chain reactions were run in different amounts and on different PCR profiles 
according to the downstream application. The primers are listed in appendix 1-5 and appendex 
7. Mastermixes was run on DNA Engine® Tetrad 2 Thermal Cycler (Bio-Rad) and GeneAmp® 
PCR System 9700 Gene (AB Applied Biosysytem). Different Taq polymerases were used to 
amplify targets of various lengths. Innu Taq DNA polymerase (Analtika Jena) was used to 
amplify products for sequencing and genotyping with microsatellite markers. The Q5 High-
Fidelity DNA Polymerase (New England Biolabs GmbH) was used for amplicons in break point 
determination. Low melting point agarose (Invitrogen TM) was used for preparative gels (0.7 to 
2%). The agarose was melted in IXTAE buffer (40 mM Tris (pH 7.6), 20 mM acetic acid and 1 
mM EDTA), stained with ethidium bromide, and run the gel on horizontal gel electrophoresis 
chambers (Analytik Jena) to resovle the DNA fragments. The DNA molecular weight markers, 
1 kb Plus DNA Ladder (Invitrogen) and 100 bp DNA Ladder (Fermentas) were used for size 
determination of the amplicons. Ethidium bromide (0.5 µg/ml final concentration) was used to 
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visulized nucleic acids under UV light. Images of the gels were taken by Molecular Imager® 
Gel Doc™ XR System and Alpha Innotech Multi Image Light Cabinet (Biozym). 
5.5 Exclusion mapping using short tandem repeats (STRs)  
In order to locate the disease gene in six (MCP101, MCP104, MCP105, MCP106, MCP117 
and MCP120) out of  twenty nine MCPH families, a set of fluorescently labelled STR markers 
of the most common MCPH loci were used to type the DNA of all available individuals in a 
pedigree. Four to six microsatellite markers were selected for each of the loci MCPH1 to 
MCPH7. Segregation of haplotypes was analyzed in healthy and affected individuals to see if 
the families are linked to or excluded from the known loci. Appendix 1 summarizes 
microsatellite markers located within the region of known loci. These microsatellite markers 
were selected for each locus from the Marshfield genetic map (Broman et al. 1998), and were 
labeled with fluorescent dyes e.g. FAM, TET, HEX and NED at 5’ end of forward primers. 
Haplotypes were constructed (not shown) and analyzed for linkage or exclusion to known loci. 
Polymerase chain reaction (PCR) amplification was carried out in a total volume of 10 μl 
containing 6 ng of genomic DNA, 10x PCR buffer II with 15 mM (MgCl2), 10 mM of 
deoxyribonucleotide triphosphates (dNTPs), 2.5 U of Innu polymerase, forward and reverse 
primers each of 10 mM. Two different amplification conditions (MS and TDM) were used as 
given in the table 5.1. After amplification, the PCR products were diluted and added 5 μl to the 
7 μl of internal size standard (1:100 diluted) (GeneScan-500 ROX; Applied Biosystems). The 
amplified markers were then separated by capillary electrophoresis on ABI 3730 genetic 
analyzer (Applied Biosystem, Foster City, CA). Allele sizes of microsatellite markers (bp) were 
determined using GeneMarker version 1.51 software (SoftGenetics) by comparison with those 
of the internal size standard. Haplotypes were constructed by EasyLinkage Plus v5.02 and 
HaploPainter v.1.043 (Thiele and Nürnberg 2005). If all affected individuals in a pedigree 
demonstrated homozygosity and unaffected parents heterozygosity for a marker set spanning 
a particular region, the family was considered as linked to that particular locus. Heterozygosity 
of the markers in affected individuals excluded the locus under investigation. 
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              Table 5.1: PCR profiles to amplify microsatellite markers for known MCPH loci 
                     MS                 TDM 
1 95 °C  5 min. 1 95 °C 5 min. 
2 95 °C 30 Sec. 2 95 °C 30 Sec. 
3 61 °C 45 Sec. 3 65 °C 30 Sec. 
4 72 °C 1 min. Decrease by 0.5°C every cycle 
Step 2-4 repeat 2 more times 4 72 °C 30 Sec. 
5 95 °C 30 Sec. Cycle to step 2 for 19 more times 
6 59 °C 45 Sec. 5 95 °C 30 Sec. 
7 72 °C 1 min. 6 55 °C 30 Sec. 
Step 5-7 repeat 2 more times 7 72 °C 30 Sec. 
8 94 °C 30 Sec. Cycl to step 7 for 19 more times 
9 57 °C 45 Sec. 8 72 °C 10 min. 
10 72 °C 1 min. 9 4 °C Forever 
Step 8-10 repeat 2 more times  
11 95 °C 30 Sec. 
12 55 °C 45 Sec. 
13 72 °C 1 min. 
Step 14-16 repeat 2 more times 
14 72 °C 30 min. 
15 4 °C Forever 
5.6 SNP genotyping methods 
The initial draft of human genome in 2001 and follow-on studies spawned a new era of 
functional characterization and cataloguing of genetic variations. Several million SNPs were 
discovered and characterized in terms of linkage disequilibrium (LD) in different populations 
(Naidoo et al. 2011). Genetic variants that are in LD tend to be inherited together. The first 
linkage map as constructed with 2,988 SNPs and used as a linkage analysis tool to investigate 
the underlying genetic causes of human diseases (Matise et al. 2003). In addition to linkage 
mapping, the genome-wide SNP analysis offers the possibility of direct dectection of structural 
genetic variations (Gibbs and Singleton 2006). New genotyping technologies were introduced 
over time, starting from 10K arrays (Affymetrix;Santa Clara, CA, in 2003) to the latest 5 million 
marker tool (Illumina; San Diego, CA). In the present studies, the following arrays were used 
for homozygosity mapping and structural variation identification. 
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5.6.1 Axiom™ Genome-Wide CEU 1 Array 
The Axiom™ Genome-Wide CEU 1 Array was used for the geonotyping of nine MCPH families 
including MCP105, MCP106, MCP118, MCP120, MCP121, MCP125, MCP129, MCP130 and 
MCP131. Genotyping was performed by our in-house core facility at the Cologne Center for 
Genomics (CCG), Cologne, Germany. Axiom Genome-Wide CEU 1 Array interrogates more 
than 587,000 SNPs and 11,000 single base insertions/deletions. The SNP content and the 
insertions/deletions on this array were selected from the dbSNP database and the Axiom 
Genomic Database. Arrays were run according to standard Affymetrix protocols (part number 
901608, www.affymetrix.com). Genotyping Console Software version 4.2 (Affymetrix) was 
used for allele calling and quality control of called genotypes. Genotyping data were exported 
in PLINK format (Anderson et al. 2010; Purcell et al. 2007) and primary data were analysed 
with the PLINK software package (version 1.07; http://pngu.mgh.harvard.edu/purcell/plink/). 
Data files were recoded in binary file format. Sex of sample was determined from the 
genotypes on X chromosome and checked against recorded gender information in the ped file 
generated from the pedigree. Samples with call rates above 96% were considered for further 
analysis. 
5.6.2 Illumina HumanCoreExome-12 v1.1 BeadChip 
Four MCPH families MCP104, MCP123, MCP165, MCP171 and a family with microcephalic 
primordial dwarfism were genotyped at the CCG using the HumanCoreExome 12v1-1 bead 
chip (Illumina Inc., San Diego, CA) according to the manufacturer’s protocol. The Illumina 
HumanExome-12 V1-1 BeadChip (microarray) targets >240,000 variants, the majority of which 
are protein-altering variants (i.e. SNPs in splice site, stop variants, non-synonymous SNPs) 
selected from ~12,000 individual exome and whole-genome sequenced genomes representing 
multiple ethnicities and range of common conditions (complex traits). Genotype calling was 
carried out with the GenomeStudio software version 2011.1 (Illumina, Inc. San Diego, USA). 
A standard protocol implemented in PLINK was used to perform quality control (QC) and data 
clean-up of genotype data (Anderson et al. 2010; Purcell et al. 2007). SNPs that had call rates 
of less than 97% were excluded from further analysis. 
5.6.3 CytoScan HD Array  
The Genome-wide Human CytoScan HD Array (Affymetrix, CA, USA) was used for DNA 
samples from MCP118 and MCP125 to analyse genomic alterations. Experiments were 
performed and analysed at ATLAS Biolabs GmbH, Berlin according to the manufacturer's 
protocol. The array contains 2,690 K markers that include 750K polymorphic SNPs and 1,900 
K non-polymorphic copy number variation (CNV) markers. These probes are spaced at 880 
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bp on average and covered 96% of all genes. Samples with QC call above 80% were 
considered for further analysis. For CNV detection, an algorithum of the Chromosome Analysis 
Suite (ChAS) v2.0 was used (Affymetrix Inc., USA). 
5.7 SNP array mapping and linkage analysis 
Thirteen consanguineous MCPH families (MCP104, MCP105, MCP106, MCP118, MCP120, 
MCP121, MCP123, MCP125, MCP129, MCP130, MCP131, MCP165 and MCP171) and a 
family (MCP68) with MPD were subjected to genome mapping and linkage analysis with the 
arrays mentioned above. Sample genders were checked by counting the heterozygous SNPs 
on the X chromosome and comparing it to the given information in pedigree file (PED file). 
Misspecification or errors of the assumed relationships in the pedigree (e.g sib-sib, parent-
offspring etc.) were evaluated with the help of the program Graphical Relationship 
Representation (GRR). Linkage analysis was performed assuming autosomal recessive 
inheritance, full penetrance, consanguinity and a disease gene frequency of 0.0001. Mendelian 
inconsistencies were detected by the program PedCheck. Multipoint LOD scores were 
calculated using the program ALLEGRO (Gudbjartsson et al. 2000). Haplotypes were 
reconstructed with ALLEGRO and presented graphically with HaploPainter (Thiele and 
Nürnberg 2005). 
5.8 Sequencing reaction 
5.8.1 Sanger sequencing 
Sanger sequencing is a linear amplification processes in which the amplified DNA act as 
template molecule. In the sequencing reaction one primer either forward or reverse is used 
which anneals to specific region of double-stranded DNA and start the enzymatic extension. 
In addition to unlabeled dNTPs, the reaction also contains fluorescence labelled 
dideoxynulceotides (ddNTPs) that terminate the elongation of the DNA reaction due to 
absence of 3’-hydroxy group. In result, DNA fragments are produced of different sizes which 
can be subsequently separated by capillary electrophoresis and detected after excitation by a 
laser. For this reason, Sanger sequencing is also called dideoxynucleotide chain termination. 
Sequences were viewed with the Seqman program of DNASTAR Software (DNASTAR, Inc. 
Madison, USA). 
PCR was performed for all coding exons of the respective MCPH candidate gene. The 15 µl 
master mix prepared for the PCR reaction included 3 µl DNA (2 ng/µl), 9.48 µl ddH2O, 1.50 µl 
10xPCR-Buffer II (10x), 0.30 µl of each primer (10 mM), 0.30 µl dNTP´s (10 mM) and 0.12 µl 
of Taq (5 U/µl). DNA was amplified using standard conditions: (1) 95 °C for 5 min; (2) 95 °C 
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30 sec ; (3) 60 °C for 30 sec ; (4) 72 °C for 30 sec (5) repeat 2-4 step 44 more times; (6) and 
72 °C for 5 min. In addition, TDM PCR profile (Table 5.1) was also used. 
Cleaning of PCR products with Exo-SAP: PCR products were diluted and cleaned up 
through Exo-SAP reaction. Two enzymes, Exonuclease I (20 U/µl, New England Biolabs) and 
the Shrimp Alkaline Phosphatase (SAP) (1U/µl, New England Biolabs) were used to remove 
the residual nucleotides from PCR products. The exonuclease I removes unused primers, 
while the Shrimp Alkaline Phosphatase removes of the residual dNTPs. For a total reaction 
mixture of 10 µl, 8 μl of the PCR product was added to the 0.075 μl Exonuclease I (20 U/µl), 
0.3 μl SAP (1U/ µl) and 1.6 μl water. The PCR was performed at 37 °C for 30 minutes, and 
then 85 °C for 15 minutes. 
BigDye® terminator cycle sequencing: Sequencing reactions (final volume of 10 μl) 
contained 2 μl clean up amplified product, 0.25 μl ABI Big Dye version1.1 (Applied Biosystems 
GmbH, Germany), 1.75 μl 5 X sequencing buffer (Applied Biosystems GmbH, Germany), 0.25 
μl primer (10 µM), and 5.75 μl water. The sequencing reaction was performed on a DNA 
Engine® Tetrad 2 Thermal Cycler (Bio-Rad Laboratories, Inc., Germany). The thermal cycler 
conditions were: (i) initial step of 96 °C for 10 seconds; (ii) 55 °C for 5 seconds; (iii) 60 °C for 
4 minutes; (iv) repeat i-iii steps 32 times. Sequencing products were purified with CleanSEQ 
buffer (Agencourt) and subsequently run on ABI 3730 genetic analyzer (Applied Biosystem), 
sequencing facility at CCG. The sequencing data were analysed with DNA Star (Lasergene) 
and Mutation Surveyor (SoftGenetics). 
 5.8.2 Pyrosequencing 
Pyrosequencing, also known as sequencing by synthesis, is the unique approach to DNA 
sequencing (Ronaghi et al. 1996). It is based on the detection of pyrophosphate (PPi) release 
during DNA synthesis. The pyrophosphate combines with adenosine phosphosulfate and 
converts into ATP by enzymatic action of ATP-sulfurlyase. ATP provides energy for Luciferase 
to oxidize luciferin and generate a flash of chemiluminesence (Fig. 5.2). The emitted light can 
be recorded by an LCC camera as a peak which is called pyrogram. The light intensity is 
proportional to the amount of nucleotides added. The excess nucleotides are degraded by the 
presence of apyrase. Pyrosequencing allows the analysis of genetic variation, genotyping and 
microorganism identification etc (Petrosino et al. 2009; Ronaghi 2001). It offers to estimate 
SNP allele frequencies in pooled sample population. To exclude the polymorphic nature of 
pathogenic variant identified in a family segregating microcephalic primordial dwarfism, allelic 
quantification in a cohort of 286 samples was carried out by pyrosequencing. 
Primer design for pyrosequencing: The Pyromark Assay Design (PSQ) Software v.1.0.6 
(Qiagen, Hilden, Germany) was used to design variant-specific PCR and pyrosequencing 
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oligonucleotide primers. The forward primer was labelled with Biotin at the 5′ site (Appendix 
7). 
Preparation of PCR products for pyrosequencing: After optimizing the PCR amplification 
conditions of the target DNA,10 µM of sequencing primer (0.36 µl for one reaction) was added 
to 1x annealing buffer (11.6 µl for one reaction). High-purity water was added to the PCR 
samples to make the final volume of 40 µl and then mixed with equal volume of mixture of 3 µl 
streptavidin Sepharose beads and 37 µl of binding buffer. This mixtures was shaken for 6-10 
minutes at room temperature to allow biotinylated PCR product capture on streptavidin-coated 
beads. Next, 80 µl mixture of PCR product and streptavidin sepharose was added to a 12 µl 
solution (sequencing primer +annealing buffer) with the help of the PyroMark Q96 Vacuum 
Prep Workstation. Hereafter mixture was incubated at 85 °C for 2 minutes to denature the 
template and cooled at room temperature. In last, parameters were selected according to 
manufacturer’s instructions on a PSQ HS96A instrument (Qiagen, Hilden, Germany) and run 
the machine. Pyrosequencing was carried out using PyroMark Gold Q96 Reagents (Qiagen, 
Hilden, Germany).The pyrosequencing data were analysed with the Pyro Q-CpG V.1.0.9 
analysis software (Qiagen, Hilden, Germany). 
        
Figure 5.2: Schematic representation of the pyrogram and biochemical reactions involved in the 
generation of the light during pyrosequencing. Adopted from (Petrosino et al. 2009). 
Solutions used for pyrosequencing 
Streptavidin sepharose (Amersham) 
Binding Buffer-pH7.6 (10 mM Tris-HCL; 2 M NaCl; 1 mM EDTA; 0.1% TweenTM 20) 
Denaturation solution-0.2 M NaOH  
Washing buffer-pH 7.6 (10 mM Tris-Acetate) 
1X Annealing buffer (1XAB)-pH 7.6 (20 mM Tris-Acetate and 2 mM Mg-Acetate) 
Enzyme-DNA Polymerase, ATP Sulfurylase, Luciferase and Apyrase 
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Substrate- Adenosine 5’ phosphosulfate (APS) and Luciferin 
5.8.3 Whole-exome sequencing 
The latest scientific advancements in next generation sequencing (NGS) technologies have 
transformed genetic studies (Mardis 2008). NGS may involve the enrichment of certain 
genomic areas, either a linkage interval, or all transcribed sequences within the interval, or, 
more recently, the entire exome (protein-coding genes). The human exome is 1% of the total 
human genome with roughly 30 million bp (Ng et al. 2009). Exome sequencing is based on 
capturing by a probe hybridization method which uses the entire set of exome as a sequencing 
target (Gnirke et al. 2009). This methodology (Fig 5.3) has been successfully used at CCG to 
identify mutations in rare recessive families. In the present study, whole-exome sequencing 
was performed in 10 MCPH families (MCP101, MCP104, MCP105, MCP118, MCP121, 
MCP123, MCP125, MCP131, MCP165 and MCP171) and a family with microcephalic 
primordial dwarfism (MCP68). DNA samples (1 μg) of one patient per family with unknown 
cause of disease was used for sequence capture. The established protocols were employed 
starting with the generation of the sequencing library before the enrichment step. Fragments 
were enriched using the SeqCap EZ Human Exome Library v2.0 kit (Roche NimbleGen) and 
subsequently, sequencing was performed on an Illumina HiSeq 2000 using a paired-end 2 × 
100-bp protocol. For the processing and analysis of the data, the inhouse pipeline Varbank 
(http://varbank.ccg.uni-koeln.de) was used at CCG. The sequence variants were prioritized for 
their likelihood to cause the disease phenotype. Variants of the highest priority were further 
validated by Sanger sequencing and tested for co-segregation in all family members.  
 
Figure 5.3: Schematic of workflow for exome sequencing. This image is taken from (Bamshad et al. 
2011). 
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5.9 RNA extraction  
Peripheral blood was collected in PAXgeneTM Blood RNA tubes to isolate total cellular RNA 
from whole blood. RNA was extracted by using PAXgene Blood RNA kit (PreAnalytiX) 
according to the manufacturer’s protocol (version, 2001). 1.5 μl of well mixed RNA sample was 
loaded onto Nanodrop ND-1000 spectrophotometer (ThermoFisher Scientific) and absorbance 
measured at 260 nm. RNA samples were diluted according to the downstream applications. 
5.9.1 Reverse transcriptase PCR (RT-PCR) 
To synthesized cDNA from RNA, Superscript II reverse transcriptase enzyme (Invitrogen) was 
used. In brief, 1 µg of total RNA was mixed with 1 µl dNTPs (10 mM), 1 µl Oligo d(T)18-Primers 
(50 µM) and filled up to 13 µl with nuclease free water in a microcentrifuge tube. This mixture 
was incubated them for 5 minutes at 65 °C to remove secondary structures of the RNA. After 
incubation, 4 µl 5X First-Strand Buffer and 2 µl DTT (0.1 M) are added to the mixture and 
incubated at 42 °C for 2 minutes. Finally, 1 µl SuperScript RT (200 U/µl) was added and 
centrifuge shortly. The reaction mixture were taken to thermal cycler and incubated at 50 °C 
for 50 minutes and 70 °C for 15 minutes. The samples were stored at -20 °C until use. 
5.9.2 Quantitative real time PCR 
For quantitative real-time PCR, 3 μl of 1:3 diluted cDNA was used as template. Primers 
(appendix), GAPDH sequences, were run in triplicate, using an Applied Biosystems 7900 Fast 
Real-time PCR System (Applied Biosystems Inc., Norwalk, CT, USA) in 384-well microtiter 
plates. The 15 µl PCR reaction comprised of 3 µl cDNA template, 0.3 µM of reverse primer, 
0.3 µM of forward primer, 0.3 µM Rox and 7.5 µl 2X qPCR Master Mix (KAPA Biosystems). 
PCR was performed as follow: (i) 95 °C for 5 min; (ii) 95 °C for 3 sec and 60 °C for 1 min; (iii) 
repeat 40 times stage ii and followed by a melting curve analysis at 60 °C to 95 °C with 2.3 °C 
increment per second at each step. Threshold cycle (Ct) values were calculated using the 7900 
Fast System SDS Software (Applied Biosystems Inc.), and further statistical calculations were 
performed using Microsoft Excel (Microsoft Corporation, Bellevue, WA, USA). For the 
quantification of the relative expression of the PLK4 mRNA, GAPDH was used as the 
endogenous control for normalization. Primers sequence are given in appendix 7. 
5.10 Cell culture and cell lines 
HeLa cell line (Scherer et al. 1953), and human fibroblasts established from wild-type and 
patient fibroblast were cultured in Dulbecco´s Modified Eagle’s Medium (DMEM, PAA 
supplemented with 10% fetal bovine serum (FBS, Biochrom), L-Glutamine (PAN Biotech) and 
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antibiotics (Penicillin/Streptomycin, 50 µg/ml Penicillin, 50 µg/ml Streptomycin, PAN Biotech). 
Cells were grown in a humidified atmosphere of 95% air and 5% CO2 at 37°C. 
5.10.1 Establishment of patient primary fibroblasts 
Primary dermal human fibroblasts were obtained by skin punch biopsy from an individual 
(MCP68-7) affected by microcephalic primordial dwarfism. The biopsy was immediately placed 
in sterile transport tube in 20 ml DMEM supplemented with antibiotics (50 mg/ml gentamycin 
(Sigma-Aldrich-G3632, USA), 75 μg/ml amphotericin B (GIBCO) and 50 µg/ml of each 
penicillin and streptomycin (PAN Biotech). Sample was shipped to the CCG in cool packs. 
Further experiments were carried out at institute of biochemistry, Cologne under sterilized 
conditions using laminar flow cabinet (Thermo Scientific). Tissue sample was cleaned in 7-10 
ml tincture of iodine (Betaisodona, Povidon-Iodine) in a falcon tube to disinfect all the infectious 
agents. The tissue was incubated in three different falcon tubes containing 15 ml PBS mixed 
with 50 mg/ml gentamycin (Sigma-Aldrich-G3632, USA), 250 µg/ml amphotericin B (GIBCO) 
and antibiotics (Penicillin/Streptomycin, each of 10 IU/mL, PAN Biotech) for 5, 10 and 20 
minutes respectively. The tissue was then incubated overnight with Dispase II (1.5 U/ml, 
Roche) diluted in PBS at 4 °C. After removing epidermis, the dermis was transferred to small 
petri dish (60x15mm) with 10 ml culture medium. The Petri plate was incubated at 37 °C. 
Medium was changed every three to four days. Fibroblasts outgrowth was checked every 4-5 
days under the simple microscope (Olympus). After one week, primary fibroblast were 
observed making ring around the tissue. Cells were grown till the ~80% confluence and the 
tissue pieces were transferred to other plates. 
5.10.2 Cultivation of human fibroblasts 
Cells were grown in different plates and confluent cells were harvested by trypsinization: 
culture medium was removed; cells were washed once with 1XPBS; 3 ml pre-warmed trypsin 
(Sigma) was added to the 15cm2 dish; incubated at 37 °C for 8-10 minutes; 10 ml of culture 
medium was added to stop the reaction; centrifuged at 1100 rpm for 5 minutes; culture medium 
was aspirated; cell contents were either plated in new dishes or were frozen at -80 °C for long 
period. In frozen case, the cell pellet was dissolved in total of 1 ml culture medium containing 
100 µl of FBS and 100 µl of DMSO. After dissolving pellet, the medium was transferred to the 
1.2 ml cryopreservation tube (VWR International). The tube was placed in Mr. Frosty and 
immediately transferred to -80 °C refrigerator. 
5.10.3 Fibroblast synchronization at G2 phase 
Patient and control cells were treated with 9 μM RO-3306 (Sigma-Aldrich, SML0569) for 22 
hrs. RO-3306 has been shown to inhibit CDK1/cyclin B1 and CDK1/cyclin A and reversibly 
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arrests cells at the G2/M border of the cell cycle (Vassilev et al. 2006). The patient fibroblast 
were treated for 22 hours and the compound was then washed away to release the arrest. 
Cells were fixed and blocked at 20, 40 and 60 minutes for centriole quantification. In case of 
mitotic index, cells were fixed at 45 minutes after removal of G2/M block. The cells were then 
proceeded for immunofluorescence. The method of fixation for immunofluorescence is 
described below in section 5.11. 
5.10.4 PLK4 construct and transfection 
 Full-length of human PLK4 (pcDNA3.1/3x myc-A, Plasmid #41165) was obtained from Add 
gene (Habedanck et al. 2005). This plasmid was used as template to generate enhanced green 
fluorescent protein (EGFP)-PLK4 wild-type plasmid. The PCR fragments were then cloned into 
pEGFP-C3 (BD Biosciences Clontech, 6082-1). Site-directed mutagenesis was performed to 
produce the mutant (PLK4 c.2811–5C>G) plasmid using a Quick-change XL mutagenesis kit 
(Stratagene, La Jolla, CA) according to manufacturer's protocol. PLK4 expression vectors were 
transfected into HeLa cells using 1mg/ml polyethylenimine (PEI, Polysciences). The high 
cationic charge density of PEI (Boussif et al. 1995) condenses the DNA into small positively 
charged complexes which are endocytosed by the cell through charged mediated interaction 
and subsequently the DNA is released into the cytoplasm (Sonawane et al. 2003). The DNA 
and PEI were mixed in the ratio of 1:3 in DMEM and incubated for 10-15 minutes at room 
temperature. HeLA cells were then transfected with wild-type GFP-PLK4 and mutant GFP-
PLK4. After 48 hours of transfection cells were processed for immunofluorescence. 
5.10.5 Determination of growth 
The 1×105 of patient (passage 2) and control primary fibroblasts (passage 5) were seeded per 
well of six-well plate. Cells were grown in normal culture medium as described above. For 
analysis, cells were trypsinized and counted every 24 hour for 6 days using a Neubauer-
Improved chamber. The counted cells were recorded for final results. 
5.11 Immunofluorescence and microscopy 
Human fibroblasts were grown either on 1000 µg/ml fibronectin (Sigma-Aldrich) coated or non-
coated 12 mm glass coverslips (Menzel-Gläser). Coverslips were placed in each wells of either 
six-well or twenty four-well cell culture plates. Approximately 1x105 cells were seeded per well. 
1-2 ml culture medium was added to each well. Cells were processed for immunofluorescence 
as follows. The media was aspirated and cells were incubated shortly with PBS. Cells were 
fixed with 3% PFA for 15-20 minutes at room temperature. Fixation agent was removed and 
cells were washed four times with PBS or tubulin stabilization buffer (TSB). Cells were 
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permeabilised with 3% BSA, 1% TritonX-100 in PBS for 3-4 minutes at room temperature. For 
tubulin staining, cells were fixed using prechilled absolute methanol for 5 min at −20 °C without 
permeabilization and all the washing steps were performed with tubulin stabilization buffer 
(TSB). After incubation with 1X PBS or TSB, the cells were blocked for 30 minutes with 
blocking buffer (1x PBG: PBS containing 5% BSA and 0.45% fish gelatin). After blocking, 
primary antibodies were diluted in blocking buffer and incubated over night at 4 °C or ≥1h at 
room temperature. Primary antibody solution was aspirated and the cells were incubated 3 
times in PBS. After this, the cells were incubated with secondary antibody for 30-60 minutes 
at room temperature protected from light. Cells were then treated with 1X PBS three times 
each for 5 minutes in dark condition. Finally, the cells were mounted on glass slides with 
Gelvatol. Dried the slides at 37 °C for 1 hour or at room temperature for 2-3 hours. Images 
were taken with a confocal laser microscope (Leica, LSM TCS SP5). Image processing was 
done with Leica LAS AF Lite software and Adobe Photoshop (CS6). 
Overexpression assay: After 48 hour transfection, HeLa cells were fixed as described in the 
previous section. Primary antibodies Cyclin A and Centrin-2 were diluted in IX PBG and 
incubated overnight at 4 °C. The mo-Cyclin A antibody (Abcam ; 1:1000) was used to indicate 
cell-cycle position (Maridor et al. 1993) while rab-centrin2 (Santa Cruz Biotechnology, sc-
27793-R; 1:500) was used to quantify centriole number and localization (Salisbury et al. 2002). 
Centriole quantification at mitotic phase: Primary antibodies used were mo-centrin 3 
(Novus biologicals, H00001070-M01; 1:500) and rat monoclonal anti α-tubulin 1:20 (Kilmartin 
et al. 1982). 
Mitotic index: Patient and control cells were fixed with pre-chilled methanol and stained with 
mo-histone H3 phosphorylated at Ser10 (Cell signaling, 9706; 1:200 dilution) and rat 
monoclonal anti α-tubulin (Y/L1/2; 1:20). 
Immunostaining of gamma tubulin: The cells were fixed and permeabalized with 100% 
prechilled methanol for 5 minutes at −20 °C. The cells were blocked and proceed for 
immunofluorescence as described previously. The mouse- γ-tublin antibody (Sigma; GTU-88 
1:300) was used as centrosomal marker. 
PLK4 signal quantification at centriole: The patient and wild-type fibroblast were stained 
with γ-tubulin and PLK4 (dianovoa, Germany; DIA-444) antibodies (Cizmecioglu et al. 2010). 
The cells were treated with 10 μM MG132 (Calbiochem®, 474790-1MG) for 5 hours before 
fixation. The MG-132 is a robust proteasome inhibitor that is cell-permeable (Elliott et al. 2003). 
The PLK4 signal was quantified using Volocity software and AlphaEaseFCTM software 
(version 4.0.0) (Alpha Innotech, San Leandro, CA, USA). 
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5.11.1 Solutions used in Immunocytochemistry 
 
Gelvatol PBG (pH 7.4) 
Polyvinyl alcohol (87%-89%, Sigma P8136) 
Glycerol 
Ionized water 
0.2 MTris-HCl (pH 8.5) 
centrifugation (5000 g, 15 min), 
2.5% Diazabicyclooktan (DABCO, Sigma Aldrich, D2522) 
Aliquot-storage: –20 °C 
 
 10X Hanks buffer     1XTubulin stabilization buffer (pH 6.8)  
137 mM NaCl      10X Hank’s buffer 
5 mM KCl      1 mm MES 
1.1 mm Na2HPO4     2mM EGTA 
0.44 mM KH2PO4     2mM MgCl2 
5 mM glucose 
4 mm NaHCO3 
 
10x Triton X-100 (25ml)    0.5% Triton X-100 (50ml) 
Triton X-100  2.5 ml    10x Triton X-100 2.5 ml 
1x PBS  22 ml    1x PBS  47.5 ml 
Store at 4 °C 
 
3% paraformaldehyde (pH 6.1, 100 ml)  PBS (pH 7.2) 
paraformaldehyde powder  3g  10 mM NaCl 
1X PBS    80ml  10 mM KCl 
0.4 M NaOH (to adjust pH 6.1)   32 mM KH2PO4 
deionized H2O (final volume)   16 mM Na2HPO4  
 
Note: IxTSB was used instead of 1X PBS for microtubule staining. 
5.12 FACS analysis 
Primary fibroblasts derived from a patient MCP68-7 carrying a mutation in PLK4 along with 
wild type were used for the apoptotic assay. The cells were treated with PBS and trypsinized 
with StemPro Accutase Cell Dissociation Reagent (A1110501, Life Technologies). The cells 
were pelleted for 5 minutes at 1100 rpm. For each FACS reaction 1x106 cells were 
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resuspended in Annexin V binding buffer (422201, Biolegend, San Diego, CA). After incubation 
with APC Annexin V (640919, Biolegend) and 7-AAD (420403, Biolegend), for 15 minutes at 
room temperature, the apoptotic cells were analyzed immediately by using the BD FACSAira 
III cell sorter (BD Bioscience USA), and data were analyzed using DIVA 6.0 (BD Biosciences) 
software. 
5.13 Preparation of protein lysates from mammalian cells 
Cells were scrapped with ice cold 1X phosphate buffered saline (PBS). The cells were spun 
for 5 minutes at 14,000 rpm, with a temperature of 4 °C in a centrifuge. PBS was drained and 
the cell pellet was resuspended in cold lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% NP-40, 0.5% Na-desoxycholat, 0.1% SDS and Proteinase Inhibitor Cocktail 
(PIC, Sigma) supplemented with protease inhibitors 1 mM DTT, 1 mM Benzamidine and 100 
mM PMSF. The amount of lysis buffer was added usually 2-4 fold volume of the cell pellet. To 
fragment the DNA, the lysed suspension was passed several times through 0.4x19 mm 
needles (27Gx3/4”, Nr.20, BD Microlane TM3) attached to 1 ml syringe. The lysate was placed 
on ice for 30 minutes and then centrifuged at 14,000 rpm for 15 minutes. The volume of the 
pellet was estimated. The sample was denatured in SDS sample buffer at 95 °C for 5 minutes. 
After denaturation, the sample was either frozen or processed further. 
5.14 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved using sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The SDS polyacrylamide gels consisted of a running and a stacking gel. The 
percentage of the resolving and stacking gel contained 10-15% and 4% acrylamide 
respectively. The gels were polymerized for 30-40 minutes at room temperature. Isopropanol 
was used to smoothen the top of resolving gel. SDS-PAGE was performed with the Biorad 
Mini-PROTEAN® Gel Chamber. For all buffers and solutions see the section 5.15. 10-40 µl of 
protein lysate and 4 µl of Page Ruler Plus Prestained Protein Marker (Fermentas; 26619) were 
loaded and the gels ran in 1X SDS PAGE running buffer first at 60 V for the stacking gel and 
then the resolving gel at 100-120 V. Gels were stained with Coomassie-Brilliant-Blue R 250 
solution for 30 minutes at room temperature and after that destained in Coomassie destaining 
solution. The gels were then used for western blots. 
5.14.1 Solution used for SDS-PAGE 
5X SDS-sample buffer    1X SDS-running buffer (pH 8.3) 
0.125M Tris/HCl (pH 6.8)    25 mM Tris-base 
20% Glycerol     192 mM Glycine 
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4% SDS     0.1% SDS 
10% ß-mercaptoethan 
Bromophenol blue 
 
Coomassie Blue staining solution (500ml) 
0.25% Brilliant-Blue R250 (Sigma) 
50% Ethanol absolute 
10% Acetic acid 
     
Destain solution  
10% Ethanol 
7% Acetic acid 
5.15 Western blot 
After proteins separation through SDS-PAGE, wet blotting was performed to transfer the 
proteins from gels to a nitrocellulose membrane (PROTRANR, Germany).The wet blot were 
set up from anode to cathode as sponge, two layers of whatman filter paper, the membrane, 
the gel, another two layers of whatman filter paper and sponge. All these were clamped tightly 
together after ensuring no air bubbles had formed between the gel and the membrane. 
Thereafter complete sandwich was submerged in transfer buffer. The blot was run at 4 °C 
overnight, and an electrical field of 15 V was applied. Next day, nitrocellulose membrane was 
blocked with Tris-buffered saline (TBS) containing 5 % dry milk for 1 hour at room temperature 
with shaking. Membrane was incubated with primary antibody diluted in IX TBS for 1 hour at 
room temperature or at 4 °C overnight with shaking. After primary antibody incubation, 
membrane was washed with 1X TBS three times each for 5 minutes. The membrane was 
incubated with corresponding appropriate horseradish peroxidase-conjugated secondary 
antibody for 1 hour at room temperature with shaking. Membrane was then washed three times 
for 5 minutes each with 1X TBS. Afterward, the membrane was incubated with 5 ml of 
Enhanced ChemiLuminescence (ECL) reagent for 1 minute. The membrane was exposed to 
an X-ray film in dark room and developed by using developer and fixer solution. The same 
membrane was stripped with 0.4 M NaOH for 15 minutes and washed twice with TBS. After 
washing step, the membrane was blocked and incubated with the new primary and secondary 
antibodies in the same way as described. 
5.15.1 Solution used for SDS-PAGE   
Wet blot buffe     10X Tris-buffered saline (TBS)  
39 mM Glycine     1 M Tris/HCl (pH 7.4) 
Materials and Methods 
 43 
48 mM Tris-HCl, pH 8.0    5 M NaCl 
20% Absolute ethanol  
 
1X Tris-buffered saline-Tween 20 (TBS-T)       
10% 10X TBS buffer  
1% Tween 20 (Sigma) 
 
ECL detection solution  
p-Cumaric acid (0.09 M in DMSO)  89 µl 
Luminol (0.25 M in DMSO)   200 µl 
1M Tris/HCl (pH 8.5)    2 ml 
Water (dH2O)     18 ml 
30% H2O2     6.1 µl 
 
 5.16 List of used antibodies for immunofluorescence and western blotting 
Antibody  Working 
concentration 
Manufacturer 
Primary antibodies for immunofluorescence 
Mouse monoclonal γ-tubulin          1:300 Sigma, GTU-88 
Mouse monoclonal centrin 3          1:500 Novus Biologicals, H00001070M01 
Mouse monoclonal pH3          1:200 Cell signaling, 9706 
Mouse Cyclin A          1:1,000 Abcam 
Rabbit polyclonal PLK4 antibody          1:100 Abcam, ab137398 
Rabbit polyclonal centrin 2          1:500 Santa Cruz Biotechnology, 27793-R 
Rat monoclonal anti Y/L1/2          1:20 (Kilmartin et al. 1982) 
Secondary antibodies for immunofluorescence 
Alexa Fluor® 568 goat anti mouse Ig          1,000 Life Technologies, A11004 
Alexa Fluor® 647 goat anti-mouse IgG          1:1,000 Life Technologies, A31573 
Alexa Fluor® 488 goat anti-mouse IgG          1:1,000 Life Technologies, A11001 
Alexa Fluor® 488 goat anti-rat IgG          1:1,000 Life Technologies, A11006 
Alexa Fluor® 568 goat anti-rabbit IgG          1:1,000 Life Technologies, A11011 
Primary antibodies for western blotting  
Mouse polyclonal PLK4 antibody          1:200  Abnova, DIA-444 
Rat monoclonal anti Y/L1/2          1:1 (Kilmartin et al. 1982) 
Secondary antibodies for western blotting 
Anti-mouse IgG peroxidase conjugated         1:10,000  Sigma, A4416 
Anti-rat IgG peroxidase conjugated         1:10,000  Sigma, A5795 
DNA staining agent 
4’,6-Diamidino-2’-phenylindole (DAPI)         1:5,000  Sigma, D9542 
Results 
 44 
6. Results 
6.1 Autosomal recessive primary microcephaly (MCPH) 
6.1.1 Homozygosity mapping in MCPH families 
In an effort to find novel genetic causes of primary microcephaly, twenty nine consanguineous 
families segregating this disorder were genotyped. Initially, affected individuals from six 
families (MCP101, MCP104, MCP105 MCP106, MCP117 and MCP118) were scanned for 
homozygous genomic regions using polymorphic microsatellite markers spanning the first 
seven loci reported to cause primary microcephaly, i.e. MCPH1 to MCPH7 loci. Of the six 
families, five showed homozgosity at known MCPH loci except MCP104. Thereafter array-
based genome mapping was performed in thirteen MCPH families to identify homozygous 
regions shared between the affected individuals. These families also included four families 
which were tested with STR markers before (MCP104, MCP105, MCP106 and MCP120). 
Genome-wide linkage analysis revealed four known MCPH loci in 12 of the 13 families. 
Homozygosity mapping was followed by exome sequencing and Sanger sequencing of 
candidate genes. In addition, ASPM was sequenced in 14 additional families, according to the 
literature, mutations of ASPM are a very common cause of congenital microcephaly among 
families from Northern Pakistan (Roberts et al. 2002). The linkage status of all studied families 
is summarized in Table 6.1.1 and Fig 6.1.1. 
 
   Table 6.1.1: Linkage status of families with primary microcephaly. 
 
MCPH1 MCPH2 MCPH3 MCPH5 
Excluded 
Families 
Total 
No. of 
families 
    2     1     2   23     1   29 
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Figure 6.1.1: A pie chart illustrating the linkage status of the MCPH families. Among 29 primary 
microcephaly families, 79.3% (purple colored) were linked to the MCPH5 locus, 6.8% (yellow) with 
MCPH1, 3.4% (blue) with MCPH2, 6.8% (red) with MCPH3, 3.4% (marigold) were excluded with all 
known MCPH loci. 
6.1.2 MCPH1 linked families 
Two primary microcephaly families, namely MCP118 and MCP125, were linked to the MCPH1 
locus which was originally mapped to chromosome 8p22-pter within a 13-cM region between 
markers D8S1824 and D8S1825 (Jackson et al. 1998). 
6.1.2.1 Family MCP118 
The MCP118 family is a large consanguineous family that was ascertained from the Punjab 
province of Pakistan (Fig 6.1.2). The family consists of seven affected individuals; two of these 
died in the first decade of their life due to unknown reason, while the rest of the patients aged 
from18-44 years. All the affected individuals had moderate intellectual disability and reduced 
head circumference (-6SD to -7SD). All the patients had impaired ability to communicate and 
to learn. There was no history of seizures and epilepsy. DNA samples from three affected 
members of the family were genotyped using Axiom™ Genome- Wide CEU 1 array 
(Affymetrix). Parametric linkage analysis was performed and mapped the peaks on 
chromosome 8, 11, 18 and 22 with maximum possible LOD score (ALLEGRO) of 3 (Fig 6.1.3). 
The underlying homozygous regions were investigated manually with the NCBI and UCSC 
genome databases. The linkage region on chromosome 8 contains MCPH1, a known MCPH 
gene (encoding microcephalin). This region maps between markers AX-11648363 (position: 
2,408,965 bp; hg19) and AX-11328718 (position: 6,404,947 bp; hg19) and results in 3.9 Mb 
linkage region. For mutation detection, all 14 exons and exon–intron boundaries of MCPH1 
6.80%
3.40%
6.80%
79.30%
3.40%
MCPH1
WDR62
CDK5RAP2
ASPM
Excluded families
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(MCPH1-001, ENST00000344683) were PCR amplified. PCR failed to amplify exons 1-2 in all 
affected individuals while PCR products were generated for normal individuals, suggesting the 
presence of a homozygous deletion. In parallel, whole-exome sequencing was also performed 
on one patient (MCP118-5) to exclude variants in other known MCPH genes. Data were 
analyzed by our in-house exome analysis pipeline (Varbank v.2.1) that successfully detected 
the homozygous deletion of first two exons in MCPHI gene (Fig 6.1.6). Due to the limitation of 
sequencing coverage, we followed by performing genome-wide CytoScan® HD array 
(Affymetrix) in one affected individual (MCP118-6) (Fig 6.1.4). Analysis of genotyping data 
demonstrated a drop off hybridization signal intensity for the 164 kb DNA segment. The 
flanking probes S-3YKOB (position: 6,246,392 bp, hg 38) and C-6BVSB (position: 6,410,707 
bp; hg38) were found in the last undeleted region. This deletion was absent in the large cohort 
of healthy individuals assessed from DGV (database of genome variant). The homozygous 
deletion affects the first two exons and the 5′ upstream region of MCPH1. To further map the 
precise breakpoints, primers across the deletion was designed (appendix 4). These PCR 
primers generated ~590 bp product (Fig 6.1.5-a). This PCR amplicon was Sanger sequenced 
which redefined the coordinates predicated by CytoScan array. To further confirm, we 
sequenced 5′-end and 3′-end of breakpoint by designing one primer of the pair in the deleted 
region. A PCR product was amplified for healthy individuals of the family while in case of 
affected individuals; no PCR product was obtained (Fig 6.1.5-b, c). The new refined 
coordinates of the break point are 6,246,012 bp to 6,410,262 bp (cytoband 8p23.1). The 
microdeletion in the MCP118 family comprises of the first 2 exons and extends ~160 kb 
upstream to the 5′ end of the MCPH1 (Fig 6.1.7). 
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Figure 6.1.2: Pedigree of family MCP118 with seven afflicted sibs and two healthy sibs along with their 
parents, showing a recessive mode of inheritance. Filled symbols represent affected individuals. A 
double line represents consanguinity. The slashed denote the deceased individuals. An asterisk 
represents the subject analyzed by CytoScan array. 
 
 
 
Figure 6.1.3: (a) Genome-wide linkage data demonstrates high peaks on chromosomes 8, 11, 18 and 
22. The highest LOD score (ALLEGRO) value was calculated z ~3. The underlying regions for these 
peaks are 3.9 Mb on chromosome 8 (2,408,965-6,404,947 bp; hg19), 1.7 Mb on chromosome 11 
(110,347,929-112,094,487 bp; hg19), 3.4 Mb chromosome 18 (903,640-4,354,096; hg19), 1.9 Mb on 
chromosome 22 (25,275,523-27,198,719 bp; hg19). (b) The LOD plot on chromosome 8 shows the 
linkage region with position of MCPH1 gene as red line, 0 refers to 2.3 cM. 
 
 
 
Figure 6.1.4: The region of MCPH1 copy number loss is highlighted by dark red line on top and 
evidenced by the reduced log2 fluorescence ratios. Each dot shows a log2 ratio of the hybridization 
signals of patient versus gender-matched control for each probe in the MCPH1. The LOH region is 
shown below the copy number state plot. The horizontal line at bottom represents the physical position 
of the oligonucleotide probes on 8p23.2-8p23.1 (hg 19), with distal p-arm probes (telomeric) on the left 
end of the plot and the proximal p-arm probes (centromere) on the right end. 
 
 
 
(b) (a) 
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Figure 6.1.5: Representative gel images of the PCR products of junction fragments to validate the break 
point in MCPH1 locus. (a) PCR product amplified with primers across the break point. Amplification was 
only detected for patients (~590 bp) (b) 3′- junction amplification: PCR was performed with one primer 
designed at the flanking region of microdeletion and with the other primer within the deleted region. Only 
DNA of healthy individuals of the family was amplified. (c) 5′- junction amplification: PCR product 
amplified with primers designed at the flanking region of microdeletion and with the other primer within 
the deleted region. Amplification was only detected for healthy individuals of the family. PCR products 
underwent electrophoresis in a 2% agarose gel and were stained by ethidium bromide. 1 Kb plus DNA 
ladder is used to estimate the molecular size of amplified DNA. 
 
Figure 6.1.6: Snap shot shows no coverage for first two exons in MCPH1. The mean coverage for the 
sample was 70x, 96 % of sequences had at least 10x coverage and 85 % of the sequences were covered 
at least 30x. 
 
(a) (b) 
(c) 
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Figure 6.1.7: The electropherogram shows the breakpoints in MCP118. Sequence coordinates are 
listed according to ensemble hg GRCh38 (December, 2013). The wild type sequence is shown below 
deletion. The arrows are pointing to the last undeleted nucleotides at both upstream 5' end and 3’ end. 
In total, a region of 164,250 bp is deleted in MCPH1. 
6.1.2.2 Family MCP125 
Family MCP125 is a large consanguineous family of Baloch origin, ascertained from District 
Tando Allahyar, Sindh, Pakistan. The DNA samples were available from 11 individuals 
including three patients (Fig 6.1.8-a). The affected individuals had normal height and reduced 
head circumference (-6 SD to -7 SD). They had mild intellectual disability and limited self care 
skills. All patients are challenged in learning and communication. There was no history of 
epilepsy. 
A genome-wide linkage analysis of the family was done by genotyping all affected individuals 
using Affymetrix Axiom™ Genome-Wide CEU 1 arrays. Due to the computational constraints, 
the large family was spilt into three subfamilies and coded as second degree of consanguinity. 
The HLOD and LOD scores were calculated with a reduced panel of 20K SNPs. Model-based 
linkage analysis was performed and we detected seven peaks on chromosome 1, 3, 6, 8, 12 
and 15 with maximum multipoint LOD scores (ALLEGRO) of z ~5.4. Next, to identify 
homozygous region shared by all three affected individuals, these chromosomes were 
analyzed again with high resolution by selecting maximum markers from the Axiom array. Five 
homozygous regions that were 6.8 Mb on chromosome 3 (51,754,424-58,561,548 bp; hg19), 
13.8 Mb on chromosomes 6 (167,510-14,056,150 bp; hg19), 3.7 and 9.3 Mb on chromosome 
8 (2,011,098-5,782,057 bp and 6,323,132-15,674,115 bp; hg19) and 4 Mb on chromosome 12 
(74,146,967-78,181,072 bp; hg19) were detected, shared by at least two individuals. Further 
calculations were carried out to look for the regions where all three cases had identical 
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haplotypes. There were many small homozygous regions but large regions of 3 Mb and 2 Mb 
were found on chromosome 6 and 8, respectively. The haplotypes were only constructed for 
chromosome 8 which contain MCPH1 (6,264,113-6,501,140 bp; hg19), a known gene for 
primary microcephaly. We tried to sequence all 14 exons and exon–intron boundaries of the 
MCPH1 (MCPH1-001, ENST00000344683). PCR failed to amplify exons 1-11 in all affected 
individuals while PCR products were obtained for normal individuals. At the same time, whole-
exome sequencing was performed on the DNA of one patient (MCP125-7). Snapshot from the 
interface of our in-house pipeline varbank (v.2.1) shows no coverage for the first eleven exons 
(Fig 6.1.12). These observations were taken as evidence for the presence of homozygous 
deletion. For CNV analysis, a genome-wide CytoScan® HD array was used in one affected 
individual (MCP125-7) (Fig 6.1.10). Genotyping data were analyzed in the same way as 
performed for the sample MCP118-6 and we detected a homozygous deletion of ~577kb that 
covered the upstream region and first eleven coding exons of MCPH1. On careful inspection 
of the genotyping data, probes C-7JUTI (position: 5,911,493 bp; hg38) and C-6UQKI (position: 
6,492,876 bp; hg 38) were found to flank the deletion. 
In similar vein like in family MCP118, to map the exact breakpoint boundaries, PCR primers 
were selected in the undeleted region (based on the CytoScan array). These PCR primers 
generated ~1030 bp product which was sequenced through Sanger sequencing (Fig 6.1.11- 
a, b, c). The Sanger sequencing redefined the above coordinates of Cyto Scan array and 
clearly delineated the breakpoint at position 5,913,147 bp to 6,490,742 bp (Fig 6.1.13). In 
MCP125, the microdeletion removed the first 11 coding exons and ~493 kb upstream in the 5′ 
region Fig 6.1.13). No exonic point mutation of MCPH1 was identified by Sanger sequencing 
of the parents. 
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(a) 
 
 
 
Figure 6.1.8: (a) Pedigree of family MCP125. An asterisk represents subject analyzed by CytoScan 
array. (b) Genome-wide scan was generated based on the genotypes of three affected siblings. The 
highest LOD score values were obtained for regions on chromosomes 3, 6, 8 and 12 with maximum 
values of z~ 3.8. (c)The LOD plot on chromosome 8 shows the linkage region with position of MCPH1 
as red line, 0 refers to 0.26 cM. 
 
 
 
 
 
 
(b) 
(c) 
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Figure 6.1.9: Haplotype reconstruction from the genotyping of three affected individuals of family 
MCP125 (Axiom TM Genome-wide Array (Affymetrix). The markers AX-11457000 (Position: 6,334,558 
bp; 14.8 cM; hg 19) and AX-11185558 (position: 8,388,493 bp; 18.1 cM; hg19) are the flanking markers 
for the shared homozygous region on chromosome 8. The markers within the MCPH1 are shown in the 
box. 
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Figure 6.1.10: The region of MCPH1 copy number loss is highlighted by dark red line on top. Each dot 
shows a log2 ratio of the hybridization signals of patient versus gender-matched control for each probe 
in the MCPH1. The LOH region is shown below the copy number state plot. The horizontal line at bottom 
represents the physical position of the oligonucleotide probes on 8p23.2-8p23.1 (hg19), with distal p-
arm probes (telomeric) on the left end of the plot and the proximal p-arm probes (centromeric) on the 
right end. 
 
              
 
Figure 6.1.11: Representative gel images of the PCR products of junction fragments to validate the 
break point in MCPH1 locus. (a) PCR product amplified with primers across the break point.  
Amplification was only detected for patients (~1030 bp). (b) 3′- junction amplification: PCR was 
performed with one primer designed at the flanking region of microdeletion and with the other primer 
within the deleted region. Only DNA of healthy individuals of the family was amplified. (c) 5′- junction 
amplification: PCR product amplified with primers designed at the flanking region of microdeletion and 
with the other primer within the deleted region. Amplification was only detected for healthy individuals of 
the family. PCR products underwent electrophoresis in a 2% agarose gel and were stained by ethidium 
bromide. 1 Kb plus DNA ladder is used to estimate the molecular size of amplified DNA. 
 
 
 
(a) (b) 
(c) 
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Figure 6.1.12: Snap shot shows no coverage for first 11 exons in MCPH1. Mean coverage for the sample 
was 65x with 95 % of target sequences being covered at least 10x and 83 % of the sequences at least 
30x. 
 
 
 
 
Figure 6.1.13: Sanger sequencing chromatograms showing the MCPH1 genomic breakpoint and 
corresponding wild type sequence from 3’ and 5’ ends. The exact positions of the breakpoint are marked 
with arrows. Numbers are based on the nucleotide position according to the human genome assembly 
GRCh38 coordinates (December, 2013). In total, a region of 577, 594 bp is deleted in MCPH1. 
6.1.3 MCPH2 linked families 
Family MCP129 was linked to the MCPH2 locus which is located on chromosome 19q13.12. 
(Roberts et al. 1999). It is a large consanguineous pedigree with four affected individuals (Fig 
6.1.14). This family was recruited from District Jamshoro in the Sindh province of Pakistan. 
The evaluation of the affected individuals was carried out at a local hospital. In all patients, 
microcephaly was noticed at birth and their head circumferences were between -5 SD and -
7SD. The patients had profound intellectual disability and speech impairment. The patients 
showed aggressive behavior; one case MCP129-1 had hypotonia in the lower limbs. All 
affected individuals were genotyped using Affymetrix Axiom™ Genome-Wide CEU 1 arrays. 
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Multipoint linkage analysis (ALLEGRO) was performed and we got a significant LOD score on 
chromosome 19. Next we selected all markers on chromosome 19 and calculated parametric 
LOD scores of z~3.9 (Fig 6.1.15). The underlying homozygous linkage region of 20.6Mb is 
flanked by markers AX-11666108 (position: 17,872,092 bp; 42.8 cM; hg19) and AX-
11668721(position: 38,486,149 bp; 63.6 cM; hg19). Map Viewer tool of NCBI and UCSC 
genome browser were used for the candidate gene identification. WDR62 was concluded as 
the only candidate gene, based on its association with the phenotype in the previous reports. 
On subsequent Sanger sequencing of the WDR62, a known missense mutation with a single 
nucleotide transversion (c.332G>C) (ENST00000401500) in exon 3 was identified that 
resulted in the substitution of arginine by threonine (p.Arg111Thr) (Fig 6.1.16). The disease 
allele segregated faithfully within the family. All the four affected cases were found to be 
homozygous for the mutation and parents were heterozygous. These result support an 
autosomal recessive mode of inheritance. 
 
       
 
Figure 6.1.14: Pedigree of family MCP129 with autosomal recessive primary microcephaly. All affected 
individuals were genotyped for genome wide linkage analysis. 
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Figure 6.1.15: The LOD plot on chromosome 19 shows the linkage region with position of WDR62 as 
red line, 0 refers to 40.2 cM. 
 
 
MCP129-7, homozygous mutant, c.332 G>C 
 
MCP129-11, heterozygous parent, c.332 G>C 
 
Wild type 
 
 
 Figure 6.1.16: Sanger traces for mutation c.332 G>C in exon 3 of WDR62. Chromatogram of 
representative homozygous affected individual (MCP129-7), heterozygous individual (MCP129-11) and 
homozygous individual for wild type allele. Arrow shows site of mutation. 
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6.1.4 MCPH3 linked families 
MCPH3 locus was first mapped on chromosome region 9q34 in a large consanguineous 
Pakistani family. A ~12 cM region of homozygosity was identified defined by the markers cen-
D9S1872- D9S159-tel (Moynihan et al. 2000). Two families MCP105 and MCP121 showed 
linkage to the MCPH3 locus. 
6.1.4.1 Family MCP105 
Family MCP105 is consanguineous family with two affected individuals. This family was 
recruited from District Khushab, Punjab, Pakistan. The pedigree (Fig 6.1.17) consists of two 
affected individuals that are born to first cousin parents. MCP105-1 aged 12 years with head 
circumference -8 SD while MCP105-2 aged 16 years with -9 SD. The patients had mild 
intellectual disability but had no other neurological symptoms or skeletal anomalies. All the 
available individuals from the family were genotyped using microsatellite markers around the 
first seven MCPH loci. The affected individuals demonstrated homozygosity at MCPH3 locus. 
The haplotype data are not shown here. To confirm further, both affected members were 
genotyped using Axiom TM Genome-wide Array (Affymetrix). Genome wide homozygosity 
mapped peaks on chromosomes 2, 9, 14, 17 and 20 with no statistically significant LOD scores. 
Next, to check if this finding is consistent with the linkage map of microsatellite markers, 
maximum markers on chromosome 9 were selected and calculated the multipoint LOD score 
(ALLEGRO) of z~1.5. CDK5RAP2 was found to reside within the small linkage interval 
(122,801,186-124,152,939; hg19) on chromosome 9 (Fig 6.1.17). The haplotypes were 
constructed by inspection the homozygous markers that spans 1.3 Mb region (Fig 6.1.18). 
To find the causal variant and exclude variants in other known MCPH genes, DNA sample of 
one patient MCP105-1 were subjected to whole-exome sequencing. Exome analysis detected 
a homozygous novel nonsense mutation p.Arg1372* in CDK5RAP2 at nucleotide position 
c.4114C>G (ENST00000349780) in exon 27 (Fig 6.1.23). This variant was corroborated by 
Sanger sequencing and segregation of the disease allele in all available individuals of the 
family. The parents were found to be heterozygous for the mutation and patients were 
homozygous (Fig 6.1.19). 
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Figure 6.1.17: (a) Pedigree of family 105 with autosomal recessive primary microcephaly. (b) Results 
of parametric linkage analysis showing LOD scores on chromosome 9 with the position of CDK5RAP2, 
shown as vertical red line. The coordinate of 0 (cM) in the figure corresponds to the 126.8 cM. 
 
(a) 
(b) 
CDK5RAP2 
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Figure 6.1.18: Haplotypes were constructed by inspection from the genotyping of Axiom TM Genome-
wide Array (Affymetrix). The flanking markers AX-11464507 (position: 122,801,186 bp; 127.4 cM; hg19) 
and AX-11432638 (position: 124,152,939 bp; 128.4 cM; hg19) spans 1.3 Mb homozygous region. 25 
homozygous markers are located within CDK5RAP2 which is shown as box. 
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MCP105-1, homozygous mutant, c.4114 C>T 
       
 
MCP105-5, heterozygous parent, c.4114 C>T 
 
 
Wild type 
  
 
 
Figure 6.1.19: Sanger traces for mutation c.4114 C>T in exon 27 of CDK5RAP2. Chromatogram of 
representative homozygous affected individual (MCP105-1), heterozygous individual (MCP105-5) and 
homozygous individual for wild type allele. Arrow shows site of mutant nucleotide. 
6.1.4.1 Family MCP121 
Family MCP121 is a consanguineous family with three affected individuals (Fig 6.1.20-A). This 
family was recruited from District Tando Muhammad Khan, Sindh, Pakistan. The microcephaly 
was noted at birth, and head circumference is ranged from -5 SD to -7 SD at the time of 
sampling. The patients had mild intellectual disability without any facial dysmorphism or other 
neurological deficit. The age of the patients varied between 7 to 17 years. 
All affected cases were genotyped using the Axiom TM Genome-wide Array (Affymetrix). 
Parametric linkage analysis was performed for recessive mode of inheritance with 20K SNPs 
and detected peaks on chromosome 9 and 21 with maximum LOD scores of z~3.3 (Fig 6.1.20-
b). The underlying homozygous regions spanned 2.1 Mb (122,473,586-124,647,279 bp; hg19) 
on chromosome 9 and 8.0 Mb on chromosome 21 (10,727,679-18,743,733 bp; hg19). The 
candidate region on chromsosme 9 harbours a CDK5RAP2, a gene already described in 
patients with primary microcephaly (Fig 6.1.20-c,Fig 6.1.21). The identification of the disease 
locus was followed by whole-exome sequencing of one affected (MCP121-4) and filtering rare 
variants in known MCPH genes. A homozygous novel nonsense mutation was identified in 
CDK5RAP2 at nucleotide position c.1279 in exon 12 (c.1279C>T, ENST00000349780) (Fig 
6.1.23). The C-to-T transition is predicted to result in a premature termination codon 
(p.Arg427*). Sanger sequencing validated the presence of the homozygous mutation in the 
two other affected siblings and a heterozygous state for the parents and two healthy sibs (Fig 
6.1.22). 
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Figure 6.1.20: (a) Pedigree of family MCP121 with autosomal recessive primary microcephaly. Filled 
symbols represent affected individuals. Empty symbols denote non affected individuals, and slashed 
symbols represent deceased individuals. (b) Genome wide scan shows two peaks on chromosome 9 
and 21, with maximum LOD scores of z ~3.3. (c) Results of parametric linkage analysis showing LOD 
scores on chromosome 9 with the position of CDK5RAP2, shown as vertical red line. The coordinate of 
0 (cM) in the figure corresponds to the 125.0 cM. 
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Figure 6.1.21: Haplotype reconstruction from the genotyping of three affected individuals of family 
MCP121 (Axiom TM Genome-wide Array (Affymetrix). AX-11136417 (Position: 122,473,586 bp; 126.8 
cM; hg19) and AX-11686466 (position: 124,647,279 bp; 128.5 cM; hg 19) markers are the flanking 
markers for the shared homozygous region. 25 markers are located within CDK5RAP2, shown as 
enclosed box. 
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MCP121-1, homozygous mutant, c.1279C>T 
 
MCP121-2, heterozygous parent, c.1279C>T 
   
Wild type 
 
 
Figure 6.1.22: Sanger traces for mutation c.1279 C>T in exon 12 of CDK5RAP2. Chromatogram of 
representative homozygous affected individual (MCP121-5), heterozygous individual (MCP121-2) and 
homozygous individual for wild type allele. Arrow shows site of mutation. 
 
 
 
 
Figure 6.1.23: Schematic representation of the exon/intron structure of CDK5RAP2. Exons (vertical 
lines) are drawn according to scale whereas introns (straight lines) are arbitrary. Both nonsense 
mutations in exon 12 and 27 of the CDK5RAP2, respectively, are shown. These are novel mutations 
identified in the current study. 
4.1.5 MCPH5 linked families 
MCPH5 is the fifth locus that was mapped at 1q25-q32 by homozygosity mapping in a Turkish 
family (Jamieson et al. 2000). ASPM (abnormal spindle–like microcephaly associated) is the 
mutated gene at this locus (Bond et al. 2002). In total, 9 families demonstrated linkage to the 
MCPH5 locus through homozygosity mapping using polymorphic microsatellite markers and 
SNP arrays. Multipoint linkage analysis (ALLEGRO) was used to calculate LOD scores. These 
families were further subjected to Sanger sequencing. 
C C C A T T G A G A G
C C C A T N G A G A G
C C C A T C G A G A
Results 
 64 
6.1.5.1 Sanger sequencing of ASPM 
ASPM contains 28 exons with an open reading frame of 10,434 bp. All coding exons and exon-
intron boundaries of ASPM (ENST00000367409) were bidirectionally sequenced in the index 
patient of each linked family. In addition, targeted Sanger sequencing were performed in 14 
MCPH families with no prior linkage mapping (appendix 6). These families were ascertained 
largely from North-West part of Pakistan. Taken together, Sanger sequencing revealed nine 
novel and three known mutations in 23 families (Fig 6.1.24). Interestingly, 13 families carried 
the already reported founder mutation p.Trp1326* in ASPM (Table 6.1.2). Moreover, two 
families harbored compound heterozygous novel mutations (Fig 6.1.24 and Fig 6.1.34). Each 
of these mutations segregated faithfully within the family. All mutations identified in ASPM are 
summarized in Table 6.1.2. 
 
 
 
 
Figure 6.1.24: Graphical representation of ASPM. Mutation identified in the current study are shown 
here. All homozygous mutations are shown above the scheme and below the compound heterozygous 
mutations. 
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Figure 6.1.25: Pedigree with haplotypes of the MCPH5 locus for the family MCP101. The affected 
individuals showed homozygosity at MCPH5 locus at chromosome 1. ASPM resides in the underlying 
homozygous region (chr1: 196,650,545-201,391,058 bp; hg19). 
Results 
 66 
   
   
 
 
Figure 6.1.26: (a) Simplified pedigree with haplotypes of the MCPH5 locus for the family MCP106. 
Haplotypes was constructed by using algorithm in Allegro v1.2c and was plotted using Haplopainter. 
Marker names and position on genetic map are displayed on the left side of the pedigree. (b) Array-
based mapping (Affymetrix Axiom genome-wide array) was also performed for genome wide linkage 
analysis. Parametric linkage analysis demonstrated a peak on chromosome 1 with the LOD score of 
z=4.21.The underlying homozygous region of 4.3 Mb (Chr1: 195,989,351-200,303,492 bp; hg19) 
(a) 
(b) 
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contains ASPM. Only three STR markers are included in the linkage region of the array based linkage 
map. 
 
 
   
 
Figure 6.1.27: Pedigree with haplotypes of the MCPH5 locus for the family MCP117. Haplotypes was 
constructed by using algorithm in Allegro and was plotted using Haplopainter. Marker names and 
position on genetic map are displayed on the left side of the pedigree. The underlying homozygous 
region (Chr1: 195,989,351-200,303,492 bp; hg19) contains ASPM. 
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Figure 6.1.28 :( a) Pedigree with haplotypes of the MCPH5 locus for the family MCP120. Individuals 
MCP120-1, MCP120-2 and MCP120-3 were genotyped using STR marker. The affected individual 
demonstrates homozygosity at MCPH5 locus. (b) Array based mapping was also performed in the 
same family and the parametric linkage analysis resulted in 16 peaks with maximum LOD score 
(ALLEGRO) of z~1.32. ASPM resides within the linkage interval on chromosome1 (178,034,744-
203,596,318 bp; hg19).Affymetrix AxiomTM genome-wide array was used for genotyping. 
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Figure 6.1.29: ( a) Pedigree and (b) graphical view of the genome-wide linkage data of family MCP123. 
Parametric linkage analysis resulted in a maximum LOD score of z~4.3 on chromosome 1. Four small 
linkage regions were detected on chromosome 1. Four small linkage regions were detected on 
chromosome 1assuming homozygosity for the ASPM locus. ASPM resides out of the linkage regions. 
Interestingly, compound-heterozygou mutations were identified in affected individuals after sequencing 
of ASPM. Illumina HumanCoreExome-12 v1.1 Bead Chip was used for genotyping. 
 
 
 
 
 
 
 
Figure 6.1.30: (a) Pedigree of family MCP130 (b) Genome wide scan based on the genotypes of 
two affected individuals. Parametric score with recessive mode of inheritance was calculated and 
detected peaks on chromosomes 1, 2,3,4,5 and 10 with maximum values of 3.6.  ASPM resides 
within the linkage interval (Chr1:188,707,774-201,392,063 bp; hg19). Affymetrix Axiom TM 
genome-wide array was used for genotyping. 
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Figure 6.1.31: (a) Pedigree of family 131 with autosomal recessive primary microcephaly. (b) Results 
of parametric linkage analysis showing LOD scores (ALLEGRO) on chromosome 1 with the position of 
ASPM, shown as vertical red line. The coordinate of 0 (cM) in the figure corresponds to the 187.5 cM. 
Affymetrix Axiom TM genome-wide array was used for genotyping. 
 
 
 
 
 
 
 
Figure 6.1.32: (a) Pedigree of family 165 with autosomal recessive primary microcephaly. (b) Results 
of parametric linkage analysis showing maximum theoretical LOD scores z=0.5 on chromosome 1 with 
the position of ASPM, shown as vertical red line. The coordinate of 0 (cM) in the figure corresponds to 
the 116.4 cM. Illumina HumanCoreExome-12 v1.1 BeadChip was used for genotyping.  
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Figure 6.1.33: (a) Pedigree of the family MCP171. (b) Genome wide scan of multipoint parametric 
linkage analysis (ALLEGRO) that demonstrated peaks on chromosomes 1 and 8 with maximum LOD 
score of z ~3.3.  ASPM resides within the linkage interval on chromosome 1 (193,038,360-199, 997,778 
bp; hg19). Illumina HumanCoreExome-12 v1.1 BeadChip was used for genotyping. 
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        Table 6.1.2: List of mutations identified in ASPM 
 
Families marked with asterisk* had Pashtun ethnicity including MCP137 and MCP138, originate from 
Afghanistan and currently living as refugees in Khyber Pakhtunkhwa, province in Pakistan. 
 
 
S.
No Family ID Gene Exon cDNA mutation  Protein Mutation Status 
1 MCP96 ASPM 23 c.9492T>G p.Tyr3164* known 
2 MCP101* ASPM 17 c.3978G>A p.Trp1326* known 
3 MCP103* ASPM 18 c.5584A>G p.Lys1862Glu known 
4 MCP106* ASPM 17 c.3978G>A p.Trp1326* known 
5 MCP117* ASPM 7 c. 2419del G p.Gly807Glu fs*7 novel 
6 MCP120 ASPM 18 c.8098C>T p.Arg2700* novel 
7 MCP123 ASPM 18 
c.6851_6854delTCTC 
c.7129C>T 
p.Leu2285Argfs*6 
p.Gln2377* 
novel 
novel 
8 MCP130 ASPM 18 c.4212G>A p. Trp1404* novel 
9 MCP131* ASPM  3 c.1232_1236delGTAAA p.Lys412Thrfs*5 novel 
10 MCP135* ASPM 17 c.3978G>A p.Trp1326* known 
11 MCP136* ASPM 14 c.3491-3494delGTAC p.Arg3491Leufs*15 novel 
12 MCP137* ASPM 17 c.3978G>A p.Trp1326* known 
13 MCP138* ASPM 17 c.3978G>A p.Trp1326* known 
14 MCP139* ASPM 17 c.3978G>A p.Trp1326* known 
15 MCP140* ASPM 17 c.3978G>A p.Trp1326* known 
16 MCP141* ASPM 17 c.3978G>A p.Trp1326* known 
17 MCP143* ASPM 17 c.3978G>A p.Trp1326* known 
18 MCP165 ASPM 18 
c.8508_8509delGA 
c.5959C>T 
p.Lys2837Metfs*34 
p.Gln1987* 
novel 
novel 
19 MCP171 ASPM 18 c.5959C>T p.Gln1987* novel 
20 MCP174* ASPM 17 c.3978G>A p.Trp1326* known 
21 MCP175* ASPM 17 c.3978G>A p.Trp1326* known 
22 MCP176* ASPM 17 c.3978G>A p.Trp1326* known 
23 MCP177* ASPM 17 c.3978G>A p.Trp1326* known 
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Figure 6.1.34: Sanger traces of families with ASPM mutations. Representative chromatogram shows 
different mutations. The mutant trances are displayed at the left while wild type (references sequence) 
is on the right. Black arrows indicate site of mutation. 
6.1.6 Excluded families 
PCR-based genotyping and linkage analysis through different arrays resulted in the exclusion 
of one family. 
6.1.6.1 MCP104 
Family MCP104 (Fig 6.1.35) is a consanguineous family ascertained from the Punjab province, 
Pakistan. This family has three affected individuals (2 males and 1 female). Both the parents 
are unaffected, and inheritance in this family was suggested to be autosomal recessive. Head 
circumference among affected individual was -7 to -9 SD below the population mean. The 
patients had mild intellectual disability and good sense of self care skills. There were no 
skeleton anomalies and no history of seizures or epilepsy. As a first investigation, the family 
was tested for linkage to the first seven MCPH loci using polymorphic microsatellite markers. 
No MCPH locus was found to have homozygous haplotypes for the affected individuals. We 
next performed Whole-genome linkage analysis by Illumina HumanCoreExome-12 v1.1 Bead 
Chip. DNA samples from two affected, both parents and one healthy sib were genotyped. 
Parametric linkage analysis was performed with reduced panel of 25 K SNPs and mapped the 
peaks on chromosome 3, 7, 15 and 17 with maximum possible LOD score of z ~2.23 (Fig 
6.1.36). These linkage regions defined a candidate region of 2.5 Mb on chromosome 3 
(63,340,627–65,817,691 bp; hg19), a candidate region of 6.0 Mb on chromosome 7 
(149,630,727–155,664,686 bp; hg19), a candidate region of 2.2 Mb on chromosome 15 
(23,236,972–25,413,558 bp; hg19) and a candidate region of 3.9 Mb on chromosome 17 
(72,646,040–76,613,675 bp; hg19). These regions were further explored for the candidate 
gene selection through UCSC genome browser and map viewer (NCBI). Genes were 
prioritized that are described or being involved in cell division, chromosome segregation and 
role in neurogenesis. There were a few possible candidate genes in these linkage regions, so 
we performed whole exome sequencing on one individual (MCP104-1). All variations were 
filtered in genes residing in the linkage intervals and no true pathogenic variant was detected 
in any gene. The underlying linkage regions were also analyzed for deletions or duplications 
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but no such event was detected. There is a possibility that this family has variation in the 
regulatory regions which are inaccessible to exome sequencing. 
 
Figure 6.1.35: Pedigree of family MCP104 with autosomal recessive primary microcephaly. 
 
 
Figure 6.1.36: Genome-wide linkage scan of family MCP104. The highest LOD score values were 
obtained for regions on chromosomes 3, 7, 15 and 17 with maximum values of 2.23. 
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6.2 Microcephalic primordial dwarfism 
A consanguineous family was ascertained with microcephalic primordial dwarfism from the 
Khyber Pukhoonkhwa (KPK), province of Pakistan. This family was named as MCP68. 
6.2.1 Family MCP68 
MCP 68 is a consanguineous family with seven affected individuals (Fig 6.2.1). The affected 
individuals exhibited profound congenital microcephaly (head circumference, from -7.44 SD to 
-15.14 SD) and substantial intrauterine growth retardation. The patients had markedly reduced 
height (-4.64 SD to -8.26 SD at current age), severe intellectual disability and speech 
impairment. Seizures were also reported in two patients MCP68-5 and MCP68-7. Aggressive 
behavior was evident in all cases, with marked delay in walking and evidence of hypertonia or 
contractures in lower limbs. In two cases MCP68-7 and MCP68-9, MRI (magnetic resonance 
imaging) findings suggested marked reduction in cortical size with simplified gyral folding. 
Brain stem and cerebellar were also reduced, with collection of increased cerebrospinal fluid 
(CSF), particularly in MCP68-9 in whom large interhemispheric arachnoid cysts were seen (Fig 
6.2.2). On ophthalmological assessment ocular abnormalities were also observed e.g., 
microcornea, cataract, contractures and corneal opacity. In patient MCP68-9, one eye was 
completely absent (Fig 6.2.2-c). Additional clinical features were also observed in some 
patients, such as postaxial polydactyly in MCP68-5 and congenital heart disease in patient 4.8. 
No significant facial dysmorphsim or any typical facial gestalt was found in any patients apart 
from prominent microcephaly. Routine karyotyping was performed on one patient (MCP68-7) 
and no numerical or gross chromosomal aberrations were detected. The detail clinical data 
are summarized in the Table 6.2.1. 
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         MCP68-5                       4.8                        MCP68-11              MCP68-7                MCP68-9 
 
Figure 6.2.1: Pedigree and photographs of affected individuals of the family MCP68 with autosomal 
recessive microcephalic primordial dwarfism. It is large consanguineous family with seven affected 
individuals including three deceased ones. An asterisk indicates that the individual is genotyped. The 
double line shows the consanguinity and slashed subjects indicates the deceased individuals. The arrow 
shows the proband in third generation. He died at age 5.5 years due to heart problem (septal defect). 
Genotypes for the mutation is showed as GG for affected and GC for heterozygous individuals (Martin 
et al. 2014). 
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Table 6.2.1 Clinical summary of the patients with PLK4 mutation in family MCP68 
 
 
 
 
 
Individual Sex Age At Examination 
 
Intellectual 
Disability 
Clinical 
features 
Neuroimaging 
OFC/SD 
(cm) 
Height/SD 
    (cm) 
MCP68-7 M 12y -7.44 
(43cm) 
 -4.64 
(115cm) 
Profound. 
Can’t sit 
unaided.  
No speech 
Microcornea. 
Cataract (R). 
Contractures. 
Epilepsy 
NA 
MCP68-9 F 5y -13.98 
(35cm) 
-6.9 
(78cm) 
Profound. 
Can’t sit 
unaided.  
No speech. 
Microphthalmia. 
Microcornea. 
Corneal opacity 
with cataract(R). 
Lumbar 
scoliosis 
Microcephaly with 
simplified gyri. 
Large 
interhemispheric 
arachnoid cyst. 
Hypoplasia of pons 
and cerebellum. 
Partial agenesis of 
corpus callosum 
(short). Enlarged 
4th ventricle 
MCP68-5 F 10.5y -13.46 
(33cm) 
8.26 (88cm Very severe. 
Few words. 
Can’t sit 
unaided. 
Polydactyly – 
partial 
duplication right 
great toe. 
Talipes 
equinovarus.2/3 
toe syndactyly 
(R+L). 
Contractures. 
Epilepsy 
NA 
MCP68-11 F 1.5y -15.14 
(30cm) 
-8.07 
(58cm) 
Very severe. 
Can’t sit 
unaided. 
Microphthalmia. 
Microcornea. 
Vitreous 
inclusions. 
Contractures 
Microcephaly with 
markedly simplified 
gyri. Hypoplasia of 
pons and 
cerebellum. Partial 
agenesis of corpus 
callosum (short). 
Venae galena cyst. 
Enlarged 4th 
ventricle. 
4.8 M 0.66Y -14.3 
(29cm) 
NA Very severe 
Few words. 
Walked with 
support age  
5.5y 
Died age 5.5Y- 
congenital heart 
disease (septal 
defect) 
NA 
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Figure 6.2.2: Structural abnormalities in the brain and eye of patients. Additional brain anomalies 
were detected through magnetic resonance imaging (MRI) of the brain. (a)Sagittal image of Patient 
MCP68-11, demonstrating severe reduction in cortical size, simplified gyral folding, thin brain stem and 
reduced cerebellar vermis size. (b) A normal age-matched control is shown for comparison: Cx Cortex, 
BS Brainstem CV: Cerebellar Vermis. (c) Structural eye abnormalities are evident in patient MCP68-9, 
with absent eye globe on the left (insert). In addition, a large region with signal intensity of cerebrospinal 
fluid (CSF) is evident within the cranium, consistent with a large interhemispheric arachnoid cyst (A.C.). 
(d) Axial sections of patient with normal anatomy for comparison. A, B, -T2 weighted images (CSF, 
white). C, D-T1 weighted images (CSF, black) (Martin et al. 2014). 
4.2.1.1 Genome-wide mapping and new locus identification  
Eight individuals that are marked by asterisk in the pedigree (Fig 6.2.1) were genotyped on an 
Illumina HumanCoreExome-12 v1.1 BeadChip. Genome-wide linkage analysis was performed 
with low resolution using 24,209 selected SNP markers, and mapped a peak on chromosome 
4. Next, chromosome 4 was selected with maximum SNPs and multipoint analysis (ALLEGRO) 
LOD score was calculated that demonstrate a region of linkage on chromosome 4, with a 
maximum LOD score of z=4.7 (Fig 6.2.3). The underlying homozygous region defined a 
candidate region of 11.7 Mb (126,454,911-138,168,552; hg19) on chromosome 4. Haplotypes 
were constructed from homozygous SNPs, obtained from high-density SNP genotyping data. 
DNA segments identical among all affected are shown in the figure 6.2.4. Homozygous region 
was further explored for the candidate gene selection through UCSC genome browser and 
map viewer (NCBI). This region contains 56 annotated and predicted coding genes. Genes 
were scrutinized manually and none of these 56 genes were reported to associate with 
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microcephalic primordial dwarfism. Therefore, homozygosity mapping established a new 
disease locus in family MCP68 (Fig 6.2.3). 
 
    
 
 
Figure 6.2.3: (a) Genome-wide scan of the family MCP68. (a-b) Homozygosity mapping identifies a 
novel locus for primordial dwarfism on chromosome 4 (4q28.3-4q28.2). Multipoint analysis (ALLEGRO) 
demonstrated high peak on chromosomes 4 with LOD score z=4.3. (c) Results of parametric linkage 
analysis showing LOD scores on chromosome 4 with the position of PLK4 which is shown by red line. 
The coordinate of 0 (cM) in the figure corresponds to the 132.1 cM (Martin et al. 2014). 
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Figure 6.2.4: Haplotype reconstruction from Illumina beadchip SNP genotyping of eight individuals of 
family MCP68 across the chromosome 4 region containing PLK4. 1000 markers were deleted to show 
clearly the homozygous region. The homozygous markers were highlighted in the enclosed rectangle. 
Asterisk* denotes flanking markers, rs10518471 and rs1425982. The rs17012739 is located within PLK4 
gene. 
6.2.1.2 Identification of a mutation in PLK4 
After identification of the new disease locus, whole exome sequencing was performed of the 
affected boy MCP68-7. First variations were filtered in all known genes associated with primary 
microcephaly and microcephalic primordial dwarfism by using in-house exome pipeline 
(Varbank 2.1) but no deleterious mutation was found. Then, high quality unknown variants  
were prioritized in the linkage interval on chromosome 4, allowing filtering for homozygous and 
 
 
* 
* 
Marker                            Mb 
Results 
 84 
compound heterozygous variations (dbSNP Build 135, 1000 Genomes Project database build 
20110521 and the public Exome Variant Server, NHLBI ESP, Seattle, build ESP6500, In-
house 511 exomes). Homozygous variations were identified in two different genes. One 
homozygous intronic mutation, c.2811–5C>G, detected in the PLK4 (encoding Polo-like kinase 
4) and the other mutation, c.1126_1132del(A)7ins(A)8, was found in LARP1B gene (La 
ribonucleoprotein domain family). Candidate genes were selected that are involved in cell 
division, chromosome segregation and embryonic development. PLK4 was the most suited 
candidate gene based on the previous literature as it has important role in cell cycle by 
regulating centriole biogenesis. Meanwhile an independent study, described the second 
mutation in two additional families with phenotypes of MPD (Martin et al. 2014). The other 
gene, LARP1B, could be assumed not to be relevant for the phenotypes. This gene has no 
known function in pathways suggested for microcephalic primordial dwarfism. Furthermore, no 
variation in this gene was detected in other two independent patients with PLK4 mutation 
(Martin et al. 2014). However, its potential role as a genetic modifier cannot be entirely 
excluded for the present family. 
6.2.1.2.1 Validation of the mutation in PLK4 
Capillary sequencing was performed to validate the variant c.2811–5C>G detected by exome 
sequencing in intron 15 of PLK4. DNA samples from all available MCP68 family members were 
bidirectionally sequenced. The affected individuals were homozygous for the mutation while 
parents and healthy sibs were heterozygous (Fig 6.2.5). This showed co-segregation of the 
mutation with the disease phenotype which are in accordance with the supposed recessive 
genetic model (Fig. 6.2.1). To investigate the disease allele frequency in the local population, 
286 samples were analyzed mostly from the North West part of Pakistan through 
pyrosequencing (Fig. 6.2.6). No mutation was detected in any of these healthy control 
individuals. Moreover, this mutation was also not found in the 1000 Genomes Project and 
National Heart, Lung, and Blood Institute Grand Opportunity (NHLBIGO) Exome Sequencing 
Project (ESP) and in other public variant databases (Martin et al. 2014). 
MCP68-7, homozygous mutant, c.2811–5C>G 
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MCP68-13, heterozygous mutant, c.2811–5C>G 
 
 
  
Figure 6.2.5: Sanger traces for mutation c.2811–5C>G in intron 15 of PLK4. Representative 
chromatogram for affected individual (MCP68-7), heterozygous parent (MCP68-13) and unrelated 
healthy control. Arrow shows site of mutation. 
 
 
               
 
Figure 6.2.6: Pyrogram traces for the detection of transversion at position (g.127,898,434 bp, hg38) of 
intron 15 in PLK4. The disease allele frequency was estimated in the DNA pool of 286 healthy control 
individuals from Pakistan. (a, top) indicates no change for nucleotide (b, middle) shows the 
heterozygous for the mutation (MCP68-4, positive control). (c, below) demonstrates the homozygous 
mutant (MCP68-9, positive control). 
 
6.2.1.3 Structure of the PLK4 
 
 The human PLK4 is located at chromosome 4q28 (127,880,861-127,899,195; hg38). The 
official name of this gene is polo-like kinase 4. The PLK4 is consist of 16 exons (Fig 6.2.7). It 
gives rise to 11 transcripts of variable length (only six are protein coding). The longest transcript 
with 3841 bases length codes for a protein of 970 amino acids. 
 
C T T C A N T T A G G
C T T C A C T T A G G
Wild type 
(a) 
(b) 
(c) 
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Figure 6.2.7: Schematic representation of the exon/intron structure of the human PLK4. Exons (vertical 
lines) are drawn according to scale whereas introns (straight lines) are arbitrary. The positions of coding 
exons (black), UTRs (grey) are indicated.The splice site mutation c.2811-5C>G is shown on intron 15. 
6.2.1.4 Transcriptional consequences of the c.2811-5G>C PLK4 mutation 
The intronic variant c.2811-5G>C (Fig 6.2.8) was further followed at the transcript level to see 
how it affects the pre-mRNA splicing. The mutation was characterized at the mRNA level and 
its biological consequences predicted by in silico analysis. 
6.2.1.4.1 In silico prediction of the alteration of the splicing 
To evaluate the splice site prediction, sequences from genomic position (Chr4: 127,896,801-
127,898,558 bp; hg38), spanning exon 15 and intron 16 of PLK4, were submitted to the online 
splice-site-prediction algorithms (http://www.cbs.dtu.dk/services/NetGene2/). Bioinformatics 
predicted the generation of a new splice acceptor site in intron 15, incorporating 4 bp of intronic 
sequence into exon16 of the PLK4 transcript (Fig 6.2.7). 
 
   
 
Figure 6.2.7: Schematics showing splice-site prediction of the altered 16th exon/intron junction. (a) 
Upper panel represents the normal acceptor site prediction. (b) Lower panel indicates the new 
predicated site (arrow). 
(a) 
(b) 
c.2811-5C>G 
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6.2.1.4.2 Reverse transcription polymerase chain reaction (RT-PCR) 
To assess the influence of the predicted splice site, RT-PCR amplifications were carried out  
targeting both exons 15 and 16 in total RNA extracted from the blood of patients and unrelated 
healthy control individuals. Upon Sanger sequencing of the amplified cDNA, it was detected 
that 4 bases, TTAG, from intron 15 were now added to the mutant transcript which resulted in 
a shift of the reading frame and caused a premature stop at the protein level (p.Arg936Serfs*1) 
while the control showed a normal transcript (Fig 6.2.8-L). In order to validate these findings 
and to exclude the presence of remaining wild-type transcripts in patients, capillary 
electrophoresis was performed on fluorescently labeled RT-PCR products. The labeled 
fragment sizes corresponded to 299 bp for the wild type and 303 bp for the homozygous mutant 
carrying the c.2811-5C>G mutation. Capillary electrophoresis revealed that the mutant 
transcript was 4 bp longer in size (303) than wild-type (299) (Fig 6.2.8-R). No residual wild- 
type transcript was detected in the homozygous c.2811-5C>G patient.  
 
 
Figure 6.2.8: cDNA sequencing chromatogram of the exon15–exon16 junction of PLK4 amplified by 
RT-PCR from patient and control RNA. The c.2811-5C>G mutation creates a new splice acceptor site 
which change the reading frame by incorporating 4 bases (TTAG) in the transcript of PLK4. Left (L), 
electropherograms of RT-PCR products from patient MCP68-7, heterozygote MCP68-10 and control 
subjects. Right (R), Genescan fragment sizing of RT-PCR products on ABI capillary sequencer, 
confirms that the mutant transcript is 4 bp greater in size than wild-type. No residual wild type transcript 
was detected in the homozygous c.2811-5C>G patient (Martin et al. 2014). 
Exon15 
Intron15 Exon16 
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6.2.1.4.3 Quantitative PCR for gene expression analysis 
Quantitative real-time PCR was performed with cDNAs from the blood of patient MCP68-7 and 
his heterozygous mother MCP68-8, along with one control samples. The relative expression 
of the target gene PLK4 compared to control level was calculated and we found that PLK4 
transcript levels were substantially reduced in the patient (Fig 6.2.9). 
 
Figure 6.2.9: Quantitative Real-Time PCR data for mRNA of patient MCP68-7 and his unaffected 
mother MCP68-9. PLK4 mRNA amounts were quantified relative to a control sample, which was taken 
as 100%. In comparison to the control, levels of functional PLK4 transcript were reduced to 23% in 
patient and 61% in the mother (n=2, Error bars represent SD). 
6.2.1.5 Consequences at the protein level of the c.2811-5G>C PLK4 
mutation 
In order to investigate the impact of the splice site mutation (c.2811-5G>C) on PLK4 structure, 
a computer program was used to construct a 3-dimensional model. The mutation was also 
characterized at the cellular level in patient MCP68-7 primary cells. 
6.2.1.5.1 Effects of the mutation on PLK4 structure 
The splice site mutation (c.2811-5G>C, p.Arg936Serfs*1) leads to the loss of 34 amino acids 
at the C-terminus. The C-terminal polo box domain (PB3) of PLK4 consists of 79 amino acids 
(aa 884 to 962). PB3 exists as a domain-swapped homodimer, composed of twisted 
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antiparallel ß sheets and a C-terminal helix (Jana et al, 2012). The crystal structure for the 
mouse Plk4 PB3 domain is available (PDB 1MBY). It shows 97% homology with the human 
PB3 domain. To predict how the mutation affects the structure of PB3, the advanced program 
WebLab ViewerPro was used. From the three-dimensional structure it can be easily 
recognized that the deletion of the last 34 amino acids destabilizes the homodimer by 
weakening the interaction between the two molecules (Fig 6.2.10). The analysis was carried 
out by Dr. W. Höhne. 
 
Figure 6.2.10: Stereo representation of the PB3 domain of murine Plk4. The structure (PDB code 
1MBY) is a dimer (monomer A in blue, monomer B in green) with extended ß-sheet interactions and 
domain swapping. Missing parts in the mutant structure are highlighted in light blue and light green 
(Martin et al. 2014).The figure is drawn for relaxed eyes. 
6.2.1.5.2 Protein quantification at the cellular level 
To determine the effects of the p.Arg936Serfs*1 mutation on the protein level, total protein was 
quantified in cell lysates derived from the patient MCP68-7 and two wild type fibroblasts. 
Immunoblotting was performed and two PLK4-specific bands were observed by using a 
published antibody to PLK4 (Cizmecioglu et al. 2010). In total cell extracts from control 
fibroblast, these bands were more obvious. They corresponded to the FL (full length) and ALT 
(alternative) isoforms. In the patient cells, the band intensity is markedly reduced as would be 
expected from the reduced mRNA amounts (Fig 6.2.11). In addition, quantitative 
immunofluorescence was used to estimate PLK4 accumulation at the centrosome in patient 
and control fibroblasts. 
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Figure 6.2.11: Immunoblotting demonstrates reduced PLK4 levels in patient-derived fibroblasts. Cell 
lysates are from asynchronous cells. The two PLK4 bands are evident for control fibroblasts on short 
exposure. Actin was used as loading control (Martin et al. 2014). 
PLK4 is a low abundance protein (Holland et al. 2012a), and to enhance the signal intensity, 
proteasomal inhibitor MG132 was added to the cells 5 hours prior to fixation. Quantitative 
analysis of the immunofluorescence signal established that PLK4 levels were significantly 
reduced (P < 0.0001) in mutant fibroblasts with total PLK4 protein levels 15 ± 0.02% of control 
levels (Fig. 6.2.12). Therefore it was concluded that the major effect of the p.Arg936Serfs*1 
alteration is a reduced PLK4 protein level due to reduced mRNA levels. Reduced protein 
stability may further reduce the level. 
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Figure 6.2.12: Immunofluorescence quantification of PLK4 at the centrosome. (a) PLK4 level was 
quantified at the centrosome by image analysis based quantitative immunofluorescence. n=3 
experiments, with 50 cells/experiment; error bars, s.e.m for n= 150 cells. P values were calculated by 
two-tailed t test: ****P ≤ 0.0001. (b) The representative image of the patient MCP68-7 and control 
fibroblasts, treated with proteasome inhibitor (MG132, 10 µM) for 5 hours before fixation. The cells are 
stained with DAPI (blue), γ-tubulin (red) PLK4 (green). Insets of PLK4 and γ-tubulin staining are shown 
at 3× magnification. Scale bar = 10 µm (Martin et al. 2014). 
6.2.1.6 Effects of reduced PLK4 protein level on the cell cycle  
PLK4 is regarded as the master regulator of centriole biogenesis (Bettencourt-Dias et al. 
2005). After revealing the consequences on the transcript and protein level, an impaired 
centriole duplication would be predicted. The number of centrioles changes during the cell 
cycle, so a mitotic stage was found the most convenient stage, to quantify centrioles in patient 
fibroblasts. 
 
 
(a) 
(b) 
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6.2.1.6.1 Centriole quantification at mitotic phase 
To quantify the centriole number during mitosis, primary fibroblasts derived from patient 
MCP68-7 and two wild type fibroblasts were synchronized at the G2/M phase border using 
RO-3306 (Vassilev et al. 2006). The patient fibroblasts were treated for 22 hours and then the 
compound washed away to release the arrest. The cells were stained with centrin 3 specific 
antibodies to visualize the centriole. A significant reduction of centriole number in patient cells 
at prometaphase and metaphase was observed. The statistical analysis revealed that 12% of 
cells had a reduced number of centrioles compared to the two controls (Fig 6.2.13). Further 
characterization of centriolar phenotypes was carried out in mitotic cells and it was found that 
29% of cells had a single centriole and 18% of cells were acentriolar (Fig 6.2.14-c). As the 
centriole is the key component of the centrosome, one might expect an impaired mitotic spindle 
formation. In fact, we observed that spindle formation was affected in patient mitotic cells. 
Furthermore, 9% of the cells were not capable to establish spindle poles and showed spindle 
disorganization, and 18% of the cells were without centrioles at both poles (balanced). 
Monopolar spindles were most frequently noticed in (63%) with single or two centrioles (Fig 
6.2.14-b). Multipolar configurations were not observed in patient cells. Genomic instability was 
rarely seen in patient (2.8%) and control cells (2.5%). 
 
Figure 6.2.13: Centrin foci (centrin 3) quantified in prometaphase and metaphase fibroblasts (n=3 
experiments, with 500 cells/experiment). Error bars, s.e.m, P values were calculated by two-tailed t test: 
*P ≤ 0.05 (Martin et al. 2014). 
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Figure 6.2.14: (a) Human fibroblast (MCP68-7, passage 5) carrying a PLK4 mutation were fixed and 
stained for immunofluorescence microscopy, using antibodies specific for centrin 3 (red) to stain  the 
centriole and YL1/2 for alpha tubulin (green). DNA is shown in blue (DAPI). The low level of PLK4 
resulted in the reduced centriole numbers and impaired spindle formation in patient cells. Cells shown 
were “balanced” cells with a broad-based bipolar spindle, “unbalanced” cells with an unequal bipolar 
spindle, “monopolar” cells with only one spindle pole, and “disorganized” cells that failed to establish a 
spindle pole. Insets show enlargement of the centrioles. Scale bar: 5 μm. (b) This column indicates 
quantification of the mitotic spindle phenotypes observed in the 12% of mitotic MCP68-7-derived 
fibroblasts (n=3 experiments, with 72 cells/experiment). (c) Quantification of the centriole phenotypes 
observed in 12% mitotic cells (fibroblasts with ≤2 centrioles (n=3 experiments, with 175 
cells/experiment). “2 together” indicates two centrioles detected at one spindle pole; 2 separate” 
indicates two centrioles detected, one at each pole. 
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6.2.6.2 Centrosome quantification at interphase 
Centrosome duplication starts at S phase and separation occurs in late mitosis (Azimzadeh 
and Bornens 2007). After quantification of centrioles during mitosis, anti γ-tubulin antibody was 
used to evaluate centrosome numbers in interphase cells of patient MCP68-7 (passage 2) and 
wild type fibroblast (passage 5). The results showed that a significant percentage of patient 
cells (7%) was without centrosomes (Fig 6.2.15-b).  
 
Figure 6.2.15: Centrosome quantification in interphase cells. (a) Images of centrosomes from 
interphase of unsynchronized fibroblasts derived from MCP68-7 and wild type stained for γ-tubulin and 
DAPI. Insets shows enlargement of the centrosomes. Scale bar: 10 μm. (b) Centrosome number is 
reduced in interphase of PLK4 deficient cells. Results were obtained from three independent 
experiments (Exp=3, n=1000). Error bars, s.e.m, P values were calculated by two-tailed t test: **P ≤ 
0.0003 for cells with 0 centrosome, *P ≤ 0.0465 for cells with 1 centrosome, *P ≤ 0.0120 for cells with 2 
centrosomes, *P ≤ 0.0514 for >2 centrosomes. 
 
6.2.1.7 Centriole overduplication assay 
 
The overexpression of PLK4 causes the mother centriole to assemble more than one 
procentriole within a cell cycle leading to the characteristic rosette-like arrangement of the 
procentriole and subsequently to centrosome amplification. The mutation p.Arg936Serfs*1 
affects the centriole duplication in 12% of patient mitotic cells. To further confirm this finding, 
overexpression assays were performed, in which the enzyme activity can be assessed by 
overduplication of the centriole and increase in number (Kleylein-Sohn et al. 2007). This assay 
demonstrated that the mutant protein was significantly impaired in its ability to steer centriole 
biogenesis. In HeLa cells 48 hours after transfection with a plasmid allowing expression of 
GFP-tagged mutant PLK4, 22.7% of all transfected cells showed evidence of centriole 
amplification, whereas GFP-tagged wild-type PLK4 triggered centriole amplification in 76.5% 
of cells (Fig 6.2.16). Importantly, Rosette-like structures were formed in transfected cells. 
Centrin 2, required for centriole duplication (Salisbury et al. 2002) was used to visualize rosette 
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structure and localization. In addition, Cyclin A antibody was used to separate G1 from S-G2 
phase cells. PLK4 was observed in the lumen of the rosette structure or to say on surface of 
the centrioles which may imply to the recruitment of centrin 2 to the PLK4 induced precursor 
structure (Fig 6.2.16). The results revealed that the mutant protein was able to localize 
effectively to the centrosome but not able to drive centriole amplification which shows that the 
residual mutant protein was also functionally impaired. 
 
 
 
Figure 6.2.16: Overexpression of PLK4 causes centriole amplification. (a) HeLa cells were 
transfected with GFP-tagged wild type and mutant (p.Arg936Serfs*) PLK4 for 48 hours and prepared 
for immunofluorescence microscopy. Cells were costained with centrin 2, Cyclin A and DNA with DAP1. 
Scale bar: 10 μm. (b-c) Data taken from three independent experiments, counting 100 cells/ experiment, 
with error bar indicating the SEM. 
6.2.1.8 Mitotic index 
To test the hypothesis that abnormal spindle formation delays mitotic progression, the mitotic 
index (MI) was measured by using Phospho-histone H3 (PH3) antibody. It is known that 
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Histone-H3 Ser-10 phosphorylation is linked to chromosome condensation (Goto et al. 1999). 
Therefore, the presence of PH3 could indicate mitotic entry of cells. Fibroblasts were 
synchronized at the G2/M phase border using RO-3306 and then released for 45 minutes. The 
mitosis index was determined in patient MCP68-7 (passage 2) and control fibroblasts (passage 
5). The result showed that for mutant cells a significantly higher percentage of cells (10%) was 
in mitosis as compared to control fibroblasts (7%) (Fig 6.2.17). 
 
Figure 6.2.17: Increased mitotic index in patient fibroblasts MCP68-7. (a) Images of fibroblasts 
stained or PH3 and DNA (DAPI). Scale bar: 10 μm (b) Quantification of mitotic index in patient and 
control fibroblasts. Results are from three independent experiments. Error bars, s.e.m, P values were 
calculated by two-tailed t test: *P ≤ 0.0389 for cells. 
6.2.1.9 Apoptosis assay 
Fluorescence-activated cell sorting (FACS) analysis was performed in patient and control 
fibroblasts. The analysis of apoptosis demonstrated that limitated apoptosis occurs in pre-
apoptotic patient cells (Fig 6.2.18). This might explain the fate of rare genomic instability seen 
both in patients and control cells or the cells with balanced configuration (no centriole at both 
poles). 
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Figure 6.2.18: (a-b) Graphical view of pre- and late-apoptotic primary fibroblasts derived from a wild-
type and patient MCP68-7 carrying mutations in PLK4 as analyzed by FACS. Uniform viable cells were 
observed in the third quarter (lower left). (c) Statistical data for pre- and late-apoptotic cells, significant 
difference was obtained for pre-apoptotic cells between wild type and patient MCP68-7 (passage 2). P 
value for pre-apoptotic cells is 0.0289 (Student’s t-test). Four independent experiments were performed. 
Error bars show SEM. 
6.2.1.10 Growth curve 
To examine further the effects of spindle abnormalities and delayed mitotic progression, the 
growth rate was determined in patient and control cells. Patient derived fibroblasts (Fig 6.2.19) 
showed reduced proliferation rate as compared to the control cells. It appears that the cell 
cycle is impaired in patient cells due to abnormal mitosis. 
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Figure 6.2.19: Growth curves of primary fibroblasts derived from patient MCP68-7 and control. It shows 
a reduced growth rate in patient cells. The data is taken from three independent experiments. Error bars 
represent standard deviativation. 
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7. Discussion 
Mammals vary in their body size. For instance, the blue whale (150,000 kg) is 75-million fold 
bigger than the bumble bee bat (2g). This variation is not only observed in body size but also 
seen in the individual organ size (Klingseisen and Jackson 2011; Oldham et al. 2000). Most 
strikingly, the human brain evolved with a dramatic expansion of the cerebral cortex over the 
course of human evolution (Rakic 2009). The mechanisms that determine the body and brain 
size are poorly understood (Barkovich et al. 2012; Klingseisen and Jackson 2011). To unlock 
the blackbox processes of brain development and cellular growth, primary microcephaly 
(MCPH) and microcephalic primordial dwarfism (MPD) have been identified as the model 
disoders on the basis of Mendelian genetics (Hu et al. 2014; Klingseisen and Jackson 2011). 
In the last few years a tremendous progress has been made in the field of genomics, such as 
the development of genetic tools and sequencing technologies. These rapid advances made 
possible targeted capture of the genome, high read depth for low level mutation and exome 
sequencing. The latter is becoming a popular approach for the identification of genes 
underlying Mendelian disorders (Hu et al. 2014; Ng et al. 2009). The list of candidate genes is 
growing and 13 genes have been identified in MCPH and more than 20 genes in MPD (Table 
3.1; Table 3.2). 
In this study, both genetic conditions were studied in a total of 30 consanguineous families 
from Pakistan. Consanguineous unions increase homozygosity of the genome and expose 
hidden recessive alleles to express in their offspring. Homozygosity mapping is a powerful tool 
to  spot segments of genomes in individuals that have been passed on to them through their 
parents (Woods et al. 2006). Hence, all these recessive consanguineous families were 
investigated through homozygosity mapping and positional candidate gene approach. Exome 
sequencing strategy complemented with homozygosity mapping was used for the identification 
of mutations. In addition, candidate-gene linkage analysis using highly polymorphic STR 
markers combined by Sanger sequencing were also used. The first part of this thesis is about 
the mutation spectrum and genetic heterogeneity of primary microcephaly while the second 
part addresses the identification of a new gene in MPD and its functional characterization at 
the cellular level. 
7.1 Mutation screening of MCPH genes 
Autosomal Recessive Primary Microcephaly (MCPH) is a rare heterogeneous genetic disorder 
characterized by reduced head circumference, low cognitive prowess and generally 
architectonically normal brains (Woods et al. 2005). Molecular genetic analysis of twenty nine 
consanguineous families revealed linkage to four out of thirteen MCPH loci and their 
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subsequent sequencing of the candidate gene resulted in different mutations (Table 6.1.2). In 
total, 23 (79.3%) families linked to the MCPH5 locus, 2 (6.8%) families to the MCPH1 locus, 1 
(3.4%) family to the MCPH2 locus, 2 (6.8%) families with MCPH3, and one (3.4%) family was 
excluded to be linked to any of the known MCPH loci (Fig 6.1.1). 
So far heterogeneity studies have been performed in only three populations like Pakistani (Gul 
et al. 2006; Roberts et al. 2002; Sajid et al. 2013), Indian (Kumar et al. 2004) and Iranian 
populations (Darvish et al. 2010). The relative frequencies of ASPM in Pakistani population is 
45% in 42 (Roberts et al. 2002), 54.5% in 33 (Gul et al. 2006), 85.7% in 21 (Kousar et al. 2010), 
and 29.8% in 57 families with MCPH (Sajid et al. 2013). ASPM has also been found in MCPH 
families from Iran and India with frequency of 14% and 33 % respectively (Darvish et al. 2010; 
Kumar et al. 2004). WDR62 (MCPH2) is the second common mutated gene that showed 10% 
(Roberts et al. 2002), 6% (Gul et al. 2006) and 8.7% (Sajid et al. 2013) prevalence in three 
independent cohorts of MCPH families from Pakistan. Furthermore, 2 out of 92 Iranian families 
and, 1 of 9 Indian families showed evidence of linkage to MCPH2. These studies and our 
findings suggest that mutations in ASPM are the most common cause of MCPH and have a 
high prevalence in the Pakistani populations (Bond et al. 2003; Gul et al. 2006; Hussain et al. 
2013). Mutations identified in the known MCPH associated genes are described in the 
following. 
7.1.1 Mutations in MCPH1 
In family MCP118, a ~164 kb region of MCPH1 (Fig 6.1.7) is deleted that covered ~160 kb of 
upstream sequence including exons 1 and 2. On manual inspection, it was found that ~164 kb 
deletion results in the loss of the first 38 amino acids, but leaves the open reading frame intact. 
Microcephalin contains three BRCA1-carboxy terminal domains (BRCT domains). The N 
terminus contains one BRCT domain (1-93 aa) whereas the C terminus has two tandem BRCT 
domains (672-833 aa) (Jackson et al. 2002; Richards et al. 2010). It was proposed that the 
mutant protein could start with the methionine that appears at position 96 aa of microcephalin. 
This microdeletion could affect the N-terminal BRCT domain of microcephalin that is known to 
interact with the centrosome and is responsible for preventing premature chromosome 
condensation (Richards et al. 2010). In the second linked family a homozygous deletion of 
~577 kb (Fig 6.1.13) covered the first eleven exons and ~493 kb upstream promoter region. It 
caused an in-frame deletion of 657 amino acids which may lead to the loss of the N-terminal 
BRCT domain. Interestingly, this deletion did not affect the inversely arranged Angiopoietin 2 
encoding gene (ANGPT2), which is situated within introns 12-14 of MCPH1. These overlapping 
microdeletions, which are not the first of its kind, suggest that the truncated gene is no longer 
functional (Garshasbi et al. 2006; Pfau et al. 2013). Mutations in MCPH1 have been reported 
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to result in premature chromosomal condensation at G2 and delayed decondensation at G1, 
cause premature chromosomal condensation (PCC) with microcephaly (Garshasbi et al. 2006; 
Neitzel et al. 2002; Pfau et al. 2013; Trimborn et al. 2004). In both of the current families, 
patients had normal height and weight and no phenotypic resemblance was observed to PCC 
syndrome. Cytogenetic analyses were not performed due to geographical remoteness, 
therefore, PCC syndrome cannot excluded be absolutely. In total 13 mutations have been 
reported in the MCPH1 gene, only two from Pakistan (Sajid et al. 2013; Venkatesh and Suresh 
2014). The current work has increased the mutation spectrum of MCPH1 in the Pakistani 
population. Additionally, it is the first to determine the precise break points in microdeletions 
>22 kb associated with MCPH genes. 
7.1.2 Mutations in WDR62 and CDK5RAP2  
In family MCP129 the missense mutation p.Arg111Thr (Fig 6.1.16) was detected in WDR62 
which was previously reported in a family from northern Pakistan (Sajid et al. 2013). This 
mutation affects the first WD repeat of the WDR62 protein which may interfere with the 
functions of WDR62. In families MCP105 and MCP121, two novel nonsense mutations were 
identified in CDK5RAP2 (Fig 6.1.23). One mutation p.Arg1372*, may result in a truncated 
protein having lost important functional domains such as the second SMC domain and 
Pericentrin and Golgi binding sites (Issa et al. 2013). The Second mutation p.Arg427* is 
predicted to results in a truncated product of 426 amino acids. It would lack most of the 215 
kDa protein except γTuRC-binding domain and a part of the N-terminal SMC-domain. 
Mutations in CDK5RAP2 are rare and only 8 different mutations have been described so far 
(Lancaster et al. 2013; Tan et al. 2014b). The CDK5RAP2 mutations described here increased 
the total number from eight to ten. 
7.1.3 Mutations in ASPM 
Sequence analysis of the ASPM gene in 23 families revealed 12 different mutations including 
3 previously published and nine novel mutations. The three known mutations p.Trp1326*, 
p.Lys1862Glu and p.Tyr3164 (Fig 6.1.24) were reported by (Kumar et al. 2004), (Darvish et al. 
2010) and (Kousar et al. 2010) respectively. To date, mutation p.Trp1326 has been described 
in 32 Pakistani families (Sajid et al. 2013) and proposed as a founder mutation in Northern 
Pakistani MCPH families (Gul et al. 2006; Gul et al. 2007; Kousar et al. 2010; Muhammad et 
al. 2009; Sajid et al. 2013). Most of these reported families with the p.Trp1326* mutation have 
Pashtun ethnicity while some reports did not mention their ethnicity information (Mahmood et 
al. 2011). Pashtuns reside mainly in Southern and Eastern Afghanistan and in North-Western 
Pakistan (Haber et al. 2012; Mahmood et al. 2011; Mehdi et al. 1999). In this study, the same 
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mutation was found in 13 further families having Pashtun ethnicity including two from 
Afghanistan who are currently living as refugees in Khyber Pakhtunkhwa, Pakistan (Table 
6.1.2), which increase the total number from 32 to 45. The nine novel mutations (Fig 6.1.24) 
identified include p.Gly807Glufs*7, p.Arg2700*, p.Trp1404*, p.Lys412Thrfs*5, p.K412Tfs*5, 
(p.K2837Mfs*34, p.Q1987*) and (p.Leu2285Argfs*6 p.Gln2377*). The last two are compound 
heterozygous mutations. These non-sense and frameshift mutations in the ASPM most 
probably induce non-sense-mediated mRNA decay and thus lead to a loss of ASPM function. 
The current study brings the total number of different ASPM mutations from 133 to 142 
(Stenson et al. 2009; Tan et al. 2014a). Of the 142 mutations, 61 were nonsense mutations, 3 
missense, 67 were small deletions or insertions leading to a change in the reading frame, eight 
were splice site mutations, two microdeletions and one with complex rearrangement (Stenson 
et al. 2009). 
7.2. PLK4 as a new gene in MPD 
In the second part of this thesis, I report the discovery of the genetic basis of microcephalic 
primordial dwarfism in a consanguineous family from Northern Pakistan. Using homozygosity 
mapping (Fig 6.2.3-a) in combination with whole-exome sequencing, a biallelic loss-of- function 
mutation p.Arg936Serfs*1 (Fig 6.2.5), was found in the Polo-like kinase family member (PLK4) 
gene on chromosome 4 (Fig 6.2.3-b). The genetic data together with the functional analyses 
at the cellular level and its involvement in the regulation of centriole number established that 
the causal mutation is related to the phenotypes seen in the patients of family MCP68 (Fig 
6.2.1). 
Microcephalic primordial dwarfism (MPD) is the umbrella term for a group of genetically 
heterogeneous human syndromes. The hallmark features of MPD is pre and postnatal growth 
restrictions and smaller brain size (Klingseisen and Jackson 2011). Defective mitosis is one of 
the molecular mechanics that reflects the effects of MPD mutated genes products (Shaheen 
et al. 2014b). Mutations have been reported in genes involved in centrosome maturation and 
centriole biogenesis, and caused primary microcephaly and short stature (Bond et al. 2005; 
Hussain et al. 2012; Kalay et al. 2011; Kumar et al. 2009; Sir et al. 2011). In the present study, 
a consanguineous family with seven affected individuals was ascertained from Northern 
Pakistan. Affected individuals displayed profound microcephaly, severe intellectual disability 
and short stature. In addition, ocular anomalies were observed as well (Table 6.2.1). The family 
was subjected to homozygosity mapping and whole-exome sequencing which revealed a 
homozygous intronic mutation, c.2811–5C>G, in PLK4. PLK4 is the most divergent member 
of all PLKs which are localized to the centrosome and have important roles in centrosome 
duplication, cells viability, mitotic progression and embryonic development (Brito et al. 2012; 
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Ko et al. 2005). Plk4-/- is reported to be embryonic lethal and arrests the embryo at E7.5 with 
a large number of mitotic and apoptotic cells (Hudson et al. 2001). Plk4+/- mice demonstrated 
genomic instability with high incidence of lung and liver cancer. These findings were thought 
to be the consequences of centrosome amplification and multipolar configurations (Ko et al. 
2005). In another independent study, failure of cytokinesis and increased levels of tetraploidy 
were shown in Plk4-/+ derived mouse embryonic fibroblasts (MEF) (Rosario et al. 2010). On 
the contrary, a recent study demonstrated that Plk4 did not regulate cytokinesis directly and 
Plk4+/- MEF cells exhibited no centrosome amplification and tetraploidy (Holland et al. 2012a). 
Moreover, Plk4+/- cells showed about 90% Plk4 protein level at centrosome, although there 
was a 50% transcript reduction which explains the competence of Plk4 to auto regulate its own 
stability through phosphorylation within a 24-amino acid phosphodegron (Holland et al. 2012a; 
Holland et al. 2010). In the present study, cells derived from patient MCP68-7 demonstrated a 
76% reduction at the transcript level and 15% of PLK4 protein accumulation at the centrosome 
which impaired the protein function, resulting in reduced centriole duplication (Fig 6.2.13). 
Meanwhile, an independent group also showed impaired centriole biogenesis and reduced 
transcript level in their mutant PLK4 cells (Martin et al. 2014). To determine that failure of 
centriole duplication in the patient is indeed due to reduction of the protein level, a centriole 
duplication assay was performed and it was found that the mutant protein was functionally 
impaired for centriole biogenesis (Fig 6.2.16). It is consistent with a recent study which 
demonstrated that Plk4-ΔPB3 expression increased significantly the percentage of cells with 
fewer than two centrioles, and related it to the reduced kinase activity (Klebba et al. 2015a). 
Hence, human PLK4 mutations may result in protein levels where PLK4 autoregulation fails to 
indemnify full kinase function but the protein still possesses enough enzyme activity to preclude 
lethality. 
From the patient cells with abnormal centrioles number, the most frequent defects (around 
63%) are the presence of unipolar spindle with a pair of centrioles and balanced spindle with 
no centriole at the poles (around 18%) (Fig 6.2.14-b). Two centrioles behave like one 
centrosome and it remains a highly stable structure in case of centriole duplication failure. 
Consequently, it will act as an MTOC (Bettencourt-Dias et al. 2005) and will not interfere with 
the cilia formation in patient cells that inherit this centrosome but would affect spindle formation 
as having one centrosome is worse than having none, which was previously described in 
Sak/Plk4 mutants in flies (Bettencourt-Dias et al. 2005). Such an observation has been further 
confirmed by an independent study which found no cilia formation in patient fibroblasts lacking 
centrioles (Martin et al. 2014). It indicates that monopolar spindles may be more challenging 
to mitotic progression than even an acentriolar configuration, however, cells were seen at 
interphase in patient cells without any centrosome, indicating successful clear up of mitosis 
(Fig 6.2.15). The most apt explanation for these results will be the formation of a bipolar spindle 
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to give license for chromosome segregation (Holland et al. 2012a). This phenomenon was 
further explained by a high mitotic index displayed in patient cells (Fig 6.2.17) which highlights 
that patient cells are spending more time in mitosis prior to bipolar segregation. In continuation 
of this experiment, a growth curve was generated which demonstrated that the cell cycle in 
patient cells is significantly impaired (Fig 6.2.19). Moreover, multipolar spindles were not 
noticed, suggesting abscence of aneuploidy in patient cells. In general, multipolar spindles 
predispose to substantial aneuploidy (Ganem et al. 2009). No previous literature and the recent 
study on PLK4 deficient cells demonstrated that monopolar spindles with reduced centriole 
number caused aneuploidy (Martin et al. 2014). It is similar to the study of plk4 depletion with 
small interfering RNA (siRNA) in time-lapse microscopy in RPE1 cells where it was found  that 
Plk4 knock-down cells have a delay in mitosis with increased number of lagging chromosomes, 
but it was not investigated whether this leads to aneuploidy (Holland et al. 2012a). To further 
address the consequences of mitotic errors, flow cytometry (Annexin V staining) was 
performed on patient cells. No increase in apoptotic cells were observed, although early 
apoptotic cells displayed low level apoptosis in patient cells (Fig 6.2.18). This could be the 
ultimate fate of cells that have no centrioles at both poles or the rare genomic instability seen 
in both patient and control. 
The findings at the cellular level were further substantiated in zebrafish studies by our 
collaborator on this project. Plk4 depletion in zebrafish demonstrated that Plk4 protein is 
required for generating normal cell numbers during development. They confirmed an overall 
size reduction, and suggest that this results from the lack of cell death because p53 is not 
involved in the growth arrest. They also detected increased mitotic index and reduction in 
centrioles number in embryos depleted of PLK4. Phenotypes indicative of ciliary defects such 
as ventral curvature, abnormal heat looping and retinal abnormalities were also described in  
morphant embryos (Martin et al. 2014). 
Why does the PLK4 mutation cause reduction of body and head size? Cellular experiments 
demonstrated that mutation in PLK4 only affects a proportion of mitosis (Fig 6.2.13). It may 
happen, that most patient cells form monospindle poles at some points in subsequent cell 
divisions during development. In such circumstances, cells will spend more time in mitosis and 
have reduced cell cycle efficiency which is enough to cause considerable dwarfism over the 
~46 mitotic cell divisions required to reach the 1 × 1014 cells of the human body. To address 
the second question, a number of possibilities can be proposed in the light of previous 
literature. Firstly, most microcephalic and Seckel syndrome proteins have been found 
ubiquitously required for cell division, and they disproportionately affect the brain size. It may 
reflect a particular requirement of neural progenitor cells to coordinate symmetric and 
asymmetric cell divisions (Lancaster and Knoblich 2012), which will be disrupted in PLK4 
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mutated cells with abnormal spindle assembly. Secondly, mitotic progression may be impaired 
disproportionately in neuroepithelial tissues (Novorol et al. 2013), where high proliferation rates 
are required during neurogenesis, a process that has a restricted time frame during 
development. Thirdly, while substantial levels of aneuploidy were not detected in PLK4 
fibroblasts, monopolar spindle formation can predispose to chromosome segregation failure in 
transformed cells (Thompson and Compton 2008), and aneuploidy itself can cause 
microcephaly (Marthiens et al. 2013). 
7.3 Conclusion and outlook  
In this dissertation, I present the identification of the genetic basis of two inherited neurological 
conditions which share the most prominent phenotype of microcephaly. Morever, this study 
revealed 13 novel mutations in known MCPH associated genes and discovered a novel genetic 
cause of microcephalic primordial dwarfism. The first part adds to the mutational spectra of 
known MCPH-associated genes. It is in agreement with the previous findings that ASPM is the 
most common mutated gene in MCPH. The observed high frequency of the ASPM mutation 
p.Trp1326* underscores its prominent role as a founder mutation in the Pashtun population 
within Pakistan and Afghanistan. On the basis of these findings, it is recommended to 
sequence particularly the p.Trp1326* mutation as the first tier when testing MCPH families with 
Pashtun ethnicity and ASPM in general for families from northern Pakistan. The second part 
uncovers a distinct primordial dwarfism-causing mutation in the Polo-like kinase family 
member, master regulator of centriole biogenesis. This work highlights the importance of 
centrosome function for normal brain and body size and extends the phenotype spectrum 
associated with centriole biogenesis genes. It provides new insights into a gene in which early 
embryonic lethality has prevented extensive study. 
In future, the identification of new genes will reveal additional critical regulators of human 
embryonic development. It will not only help to uncover the molecular pathology of both 
heterogeneous diseases but also pave the way to understand some longstanding questions in 
the field of developmental biology. The mechanism as to how various MCPH-associated 
proteins cause the same human phenotype and how the same centrosomal genes are 
implicated in primary microcephaly and microcephalic primordial dwarfism, is not precisely 
known. In short, the expected outcome of this project will result in improved diagnostics and 
counseling for primary microcephaly and related syndromes which are relatively more 
prevalent in Pakistan. The prognosis can be predicted and, the follow-up/treatment may be 
optimized to each individual/diagnosis.
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9. Appendix 
Appendices 
Appendix 1 
List of microsatellite markers used for exclusion mapping. These markers spanning the first 
seven MCPH loci. Of note, the CEP152 (MCPH4) locus name is now designated as MCPH9 
(OMIM# 614852) according to the new nomenclature. See 5.5 for details. 
Locus Marker PCR 
Prog 
Dye Repe-
at unit 
PCR 
product 
size (bp) 
Position 
(cM) 
Physical position  
(hg19) 
MCPH1 D8S518 MS Fam Di 229-253 5.6 4487605-4487855 
 D8S1798 MS Tet Di 145-165 6.7 5103286-5103608 
 D8S1742 MS Fam Di 130-150 7.7 6214007-6214142 
 D8S277 MS Fam Di 148-180 8.34 6516725-6516870 
 D8S1819 TDM Fam Di 207-223 10.0 6749967-6750187 
 D8S1825 MS Hex Di 127-143 15.4 8924866-8924998 
MCPH2 D19S213 MS Hex Di 174-184 59.4 34111259-34111441 
 D19S425 MS Fam Di 252-280 59.4 35493932-35494196 
 M19SH14 MS Hex Di   293 61.0 36474261-36474287 
 D19S224 MS Tet Di 240-262 61.5 36528072-36528329 
 D19S896 MS Fam Di 194-220 62.0 37478642-37478839 
 D19S570 MS Fam Di 186-210 62.0 37727743-37727942 
MCPH3 D9S302 TDM Fam Tetra 232-316 123.3 117081115-117081372 
 D9S934 MS Hex Tetra 206-230 128 121095754-121095977 
 D9S1850 MS Ned Di 218-230 132.1 123450263-123450486 
 D9S1682 MS Hex Di 200-208 132.1 124993185-124993386 
 D9S1881 MS Fam Di 220-236 135.9 126979479-126979708 
 D9S1825 MS Ned Di 127-145 136.5 127888132-127888262 
MCPH4 D15S659 MS Hex Tetra 166-210 43.5 46374008-46374191 
 D15S1006 MS Fam Di 208-228 44.9 47546963-47547176 
 D15S992 MS Fam D1 256-274 45.6 48839742-48840011 
 D15S126 TDM Fam Di 188-218 45.6 49302271-49302458 
 D15S1016 MS Hex Di 239-267 47.3 53532829-53533077 
 D15S962 MS Fam Di 282-294 47.9 56575068-56575351 
MCPH5 D1S2816 MS Fam Di 248-252 211.1 196650545-196650792 
 D1S1660 MS Fam Tetra 218-250 212.4 198611347-198611574 
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 D1S373 MS Hex Tetra 283-330 214.0 200254486-200254796 
 D1S1723 MS Hex Di 167-181 215.1 201390888-201391058 
 D1S2655 MS Fam Di 224-260 216.8 202565270-202565517 
MCPH6 D13S787 MS Hex Tetra 231-271 8.87 24380738-24380989 
 D13S742 MS Hex Tetra   364  10.7 25282814-25283171 
 D13S283 MS Fam Di 128-153 11.5 25600985-25601113 
 D13S1294 MS Hex Di 247-273 12.9 26476909-26477159 
 D13S221 MS Ned Di 318-366 12.91 26576866-26577100 
 D13S1304 MS Hex Di 149-165 13.45 27370064-27370222 
MCPH7 D1S2797 MS Fam Di 148-180 75.7 46933592-46933758 
 D1S2874 MS Hex Di 230-240 75.7 47908120- 47908484 
 D1S2134 MS Ned Tetra 249-301 75.7 48281268-48281554 
 D1S197 MS Hex Di 115-129 76.3 50750498-50750635 
 D1S427 MS Fam Di 275-297 76.3 69213345-69213632 
Appendix 2 
Primers used for PCR and Sanger sequencing of MCPH1 
MCPH1-Ex1F CTCCCGCCTCACCTACAGAG 
MCPH1-Ex1R AGCAGTACGGGGGAGGAAG 
MCPH1-Ex2F GTCTCAAACCCCTGACTTCG 
MCPH1-Ex2R TCCTCCTCCTCACTCAATGC 
MCPH1-Ex3F TTCACCGTTGTAACTGGAACAG 
MCPH1-Ex3R TCCCCCTAGGCAGAGTTAGG 
MCPH1-Ex4F GGGAAGTTTGATTTATACTGACTTTTG 
MCPH1-Ex4R ACCACAGGCTTTTCCATTTC 
MCPH1-Ex5F TTGCCAGTTCACATACAGTGC 
MCPH1-Ex5R TATTATGGCTCCCAGCCAAG 
MCPH1-Ex6F CAACATCACTGCCTGTGGAG 
MCPH1-Ex6R CAAAGCCAGCCATGAAATAAG 
MCPH1-Ex7F CAGGCAAGTTGACTTTAAGATCC 
MCPH1-Ex7R GAGCAATGGATTCTGTAGCAAG 
MCPH1-Ex8-1F CCCTTAAGTGGAAATGAGAAGAAC 
MCPH1-Ex8-1R CAAACGATACTTCTCTTCAAACG 
MCPH1-Ex8-2F TCATCACCATCTTTCACTCACC 
MCPH1-Ex8-2R AACTGAGCAGGGCTTGATG 
MCPH1-Ex8-3F CTGGAGGCTCTTAGCTGTGG 
MCPH1-Ex8-3R CTTTTCAGACCAACCGCTTC 
MCPH1-Ex8-4F TTCGAGTTGCGTGACTTCTG 
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MCPH1-Ex8-4R TCATTGGAATGATCAAATGCAC 
MCPH1-Ex9F TTTATTTAAAAGGCCTATAACTTCCTG 
MCPH1-Ex9R GCAAACAACGCTTTCAGTTTC 
MCPH1-Ex10F GCTTTGGGGACAGTATCTGAG 
MCPH1-Ex10R CTGCCTAAACAACCCCAGAG 
MCPH1-Ex11F TTTATTTCCCCAGGTTTCAAAG 
MCPH1-Ex11R GACCAACAGGAGGAAAGACG 
MCPH1-Ex12F TTCATAACATTTATGCAACATGAAG 
MCPH1-Ex12R AAAAGGTGTTAAGTTCTGTGAATGTC 
MCPH1-Ex13F TGTCATCATCTTCTCTGGATTCTC 
MCPH1-Ex13R CGTCTGCTAACAGCAAGGAG 
MCPH1-Ex14F TTGTATTGAATTTCGTTTCACG 
MCPH1-Ex14R TCTTAAGAACCACAACACATGG 
 
Appendix 3 
List of primers used for PCR amplification and sequencing of ASPM 
ASPM-Ex1-1-F GATTCCGCTACCGTTCTCAC 
ASPM-Ex1-1-R AAGGAGACCTGCAGAAGTGG 
ASPM-Ex1-2-F GAATTCACTCCCACGACCTC 
ASPM-Ex1-2-R AAGAGCCACCCACAGTTATTG 
ASPM-Ex2-F TTCTTATAATTAAGCAGATAGGGTAGG 
ASPM-Ex2-R GCAATATTACTTCAAGCCTGTTATC 
ASPM-Ex3-1-F ATGTTTTAACCATTCTGTGATTTACTC 
ASPM-Ex3-1-R ACGTACAGAGAGTGGCAAGC 
ASPM-Ex3-2-F CCCCCAACAGAAAACAATTC 
ASPM-Ex3-2-R GGGGATAAAATAGGATTAACTGACTC 
ASPM-Ex3-3-F AGCCTGTGCATTTGGAATC 
ASPM-Ex3-3-R ACCCACTGCACTGTTGAGAC 
ASPM-Ex3-4-F GAAGGCCACCTGTACCAGAG 
ASPM-Ex3-4-R AGGAAATGTACCCAGCAAATAAG 
ASPM-Ex4-F TCATAGCATTAGTGCGTGGAG 
ASPM-Ex4-R TTCTTCCAGGCTGTTATTCAAC 
ASPM-Ex5-F TTCAGTGTTTTAAAGATGGTATTGC 
ASPM-Ex5-R GCTAATGAACAGGGAATTATGC 
ASPM-Ex6-F TGAAATTGCATTTTATTGCTG 
ASPM-Ex6-R AAAAACACAAAATCTCTTGAATG 
ASPM-Ex7-F TTTCCCACTGATATACTCTCCTTG 
ASPM-Ex7-R AAAAGATGAATCAAGCTAACCTAATG 
Appendix 
 122 
ASPM-Ex8-F TTATGGTCTGCCATTCCTCAG 
ASPM-Ex8-R GGAATGAGGGTGGAGGAAG 
ASPM-Ex9-F TTGCTACCCTACACTTTTTGTTTTAC 
ASPM-Ex9-R GATGGGACTCACCAGACAGG 
ASPM-Ex10-F CAGAATGATTTGGAGGATTTG 
ASPM-Ex10-R GACATAACATTGATGTACCACTTCC 
ASPM-Ex11-F ATGGAGCAACAGAGTTTTGAG 
ASPM-Ex11-R AAAAGAAAAGGTTGTCCATTAGC 
ASPM-Ex12-F AGAGGTAAAACTTATTCTCCTCACTG 
ASPM-Ex12-R GTTACTGGGGCAAAATAAACC 
ASPM-Ex13-F TCCATTTCAGGCACTTTATTTTC 
ASPM-Ex13-R AAGAAATTCAAGAAAAGACTTCAGG 
ASPM-Ex14-F CTGCCTTTATTATTCACAGGTATTC 
ASPM-Ex14-R CTATTATGCAGGAGGAAAGGAG 
ASPM-Ex15-F TCCCTTTTGGTTACTTTTCC 
ASPM-Ex15-R AAAAACCCACAAAAGATAAAAAC 
ASPM-Ex16-F AATTCAATAATAAAGTCTCAGAAGATG 
ASPM-Ex16-R ATACTCATACCTCCCCAACC 
ASPM-Ex17-F TTCCAAAGATGAACACAAGAAG 
ASPM-Ex17-R ACCATAACGAGCTTTTCAGG 
ASPM-Ex18-1-F TGAATTGGCTACAGGTATATCAATG 
ASPM-Ex18-1-R CTTGTGATTGCATTTTACGTTG 
ASPM-Ex18-2-F GTTACAATTCAGAGGCATTGG 
ASPM-Ex18-2-R CGCTCAATCTTTCCTTTCAG 
ASPM-Ex18-3-F AGAAAAGATTTCGGTGCTTTC 
ASPM-Ex18-3-R AGACTGCAGCACAATGACAG 
ASPM-Ex18-4-F TCATTTCCGAGCTTATATTTTTG 
ASPM-Ex18-4-R AATACTGCCGAGCCTTTCTC 
ASPM-Ex18-5-F AGGATACCTTGTCCGAAAGC 
ASPM-Ex18-5-R AAATCACAGCTGCCTTTGTC 
ASPM-Ex18-6-F ACGCCAGCTAATCAAACAAC 
ASPM-Ex18-6-R CTTTTGTTGCACATGCATTC 
ASPM-Ex18-7-F TGTGGAAGGGAAAAACACTGAG 
ASPM-Ex18-7-R ATAAAAGTGGCTGCCCTGTG 
ASPM-Ex18-8-F AAGACAGCAATTAAAATCCAATCTG 
ASPM-Ex18-8-R GAATGAGAGTTGCGGCTATATG 
ASPM-Ex18-9-F CAGCAAAGATACTGGGCAATG 
ASPM-Ex18-9-R ATGCTGCCTCTGCAGTTTTG 
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ASPM-Ex18-10-F GGGCTGCTACTTTCATCCAG 
ASPM-Ex18-10-R GCATGTTTCCAAGTCTGAAATG 
ASPM-Ex18-11-F AAGGGCTGCAGTTCTCATTC 
ASPM-Ex18-11-R AATAATAATGGCAGCCTGGTG 
ASPM-Ex18-12-F CTTGTGTTCAGGCAGGTTTTC 
ASPM-Ex18-12-R GGCTGCCATCTTTTCCTCTG 
ASPM-Ex18-13-F GCTGCTTTTAGAGGCATGAAAG 
ASPM-Ex18-13-R TTGGTCAAAAGAAAGACTCACAG 
ASPM-Ex19-F ATGCAATTTATTTTTGTCTGCAC 
ASPM-Ex19-R CAGTACGAGAGATGTATTTTGTTTCC 
ASPM-Ex20-F ACTTCTTTCGTGTGCGTGTG 
ASPM-Ex20-R TGTGTGAAATAAATGCATACTTAGGTC 
ASPM-Ex21-F TGAAACATGGCATTCTTAGAC 
ASPM-Ex21-R TCAGTGCTCTTGTCACTTACC 
ASPM-Ex22-F TGATTAACTTAGGAGGCAGATACTTG 
ASPM-Ex22-R AACCCTCAAATCATTGTAACAGC 
ASPM-Ex23-F TGGACTGGAAAGGTTTTTGC 
ASPM-Ex23-R TGAGTTATTCTACCGGCTAATGC 
ASPM-Ex24-25-F GATGTAGATATAAATAGAAAACATTGG 
ASPM-Ex24-25-R CAGGGGCATATTTGTTGAC 
ASPM-Ex26-F AAAGTCCTTTGCACTTGCTG 
ASPM-Ex26-R TTTATCCGTGCAAAAAGCAG 
ASPM-Ex27-F GCGACAGAGCAAGAGAGACC 
ASPM-Ex27-R TGTTGTTTCTCCACTGAAAAGC 
ASPM-Ex28-F AAGGTGAAGGTAACTCTAAAGAGAAG 
ASPM-Ex28-R TTTTATGAAAATTCCTCAACTTACC 
 
Appendix 4 
Primers used for junction amplification and sequencing in MCPH1 
MCP118-F ACTCATTCTGCTTGCTGCAC 
MCP118-R GGCAAATTGTTTGCTATCTCC 
MCP125-F CGATTTTGAAGGTATCTTTCTCC 
MCP125-R CTTTCAGAAACAAGAACCCAAG 
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Appendix 5 
List of primers used for WDR62 sequencing. 
WDR62-AMP.1-F GCCCCCATTGGTTCTAAGC 
WDR62-AMP.2-F GGGTGTTGAATGTAGCAGGAC 
WDR62-AMP.3-F ATTTGTGGGCTTTTCTGGTG 
WDR62-AMP.4-F AGGCAGAAGAGGGCAGAGTC 
WDR62-AMP.5-F GACTTGGAGTGGGGACGAG 
WDR62-AMP.6-F CCATTTGGAAGAGCTTCTTAGAG 
WDR62-AMP.7-F TGGGTGTCTTAGACCCAAGG 
WDR62-AMP.8-F GATGGATGGCCACAAATACC 
WDR62-AMP.9-F TTGCACGATACCTGTTTATCTTTAAC 
WDR62-AMP.10-F CTCTGCATCACTGCCTCTTG 
WDR62-AMP.11-F ATTGGTGAAACTCCCAGCTC 
WDR62-AMP.12-F TTCAACACGGCTCCCTTTAC 
WDR62-AMP.13-F GAACCAAAGACCCCTTCTCC 
WDR62-AMP.14-F TTGATTGATGGCTCTTGCAG 
WDR62-AMP.15-F TCAGCTTGAGATGGGGTTTC 
WDR62-AMP.16-F AGAGTCCCATGTGCTGTGC 
WDR62-AMP.17-F CAGGAGCATCTGGAGAATGG 
WDR62-AMP.18-F CACATGGAGCTTAGCACAGG 
WDR62-AMP.19-F CTTCTGACTTCTGGGTTGTGG 
WDR62-AMP.20-F CAGATGGGCTGTGTGAAATG 
WDR62-AMP.21-F CTGCTGGCATGGTTCCTG 
WDR62-AMP.22-F AGGGGGCATTTGGAGGAG 
WDR62-AMP.23-F TACCATCCCTCCTCCAGATG 
WDR62-AMP.24-F CCCACTGAGCCTGGAAGAC 
WDR62-AMP.25-F CTGCTCGTACCCTGTGTCTG 
WDR62-AMP.26-F CCGGATGTCCAGCCTAGC 
WDR62-AMP.27-F GGGACCCAGAGAAGTGTTCC 
WDR62-AMP.1-R GAACAACCTGAGGGGACTGG 
WDR62-AMP.2-R GAGCTGGGACACAAATCCAG 
WDR62-AMP.3-R CGTCTCCTCTGGTCACTGC 
WDR62-AMP.4-R TGCGTCCTCTCATGTAGCTC 
WDR62-AMP.5-R GAGAGTAGGCCCAGAAGCAG 
WDR62-AMP.6-R AACCTGTGTGGTCAATGCTG 
WDR62-AMP.7-R TGGGTATTTGTGGGATGGAC 
WDR62-AMP.8-R AGAGGGTTACTGCTGCTTGG 
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WDR62-AMP.9-R TTGCCCTCATGGAACCTAAC 
WDR62-AMP.10-R CTCAGCTCCCCAGAGACG 
WDR62-AMP.11-R TATTCACAGCCCCTCATTCC 
WDR62-AMP.12-R AACTCCCAGCTGTCATCCAC 
WDR62-AMP.13-R CGGCCCCAGTCATTATTCTG 
WDR62-AMP.14-R ATTCCTTCCCAGCTTCTTGG 
WDR62-AMP.15-R GGCACAGGTCTCAGGTGTG 
WDR62-AMP.16-R ACTCCCACAATCCAAACTGG 
WDR62-AMP.17-R TCAGCTGTGAGTGTGCTAAGG 
WDR62-AMP.18-R GCTGGGATTACAGGTATCAGC 
WDR62-AMP.19-R ACTGAGCCTGGAAGGATGAC 
WDR62-AMP.20-R GGAGTGGGAGTCAGCCTAAG 
WDR62-AMP.21-R CCACTGGGAAGGCAGAGAG 
WDR62-AMP.22-R CAGAATCCTCAGGCAGCAG 
WDR62-AMP.23-R CGTCTTCCAGGCTCAGTGG 
WDR62-AMP.24-R CTCTCCACTCACCCTCCTG 
WDR62-AMP.25-R CACAGAACTGATGGCTAGGG 
WDR62-AMP.26-R CGAATGAATGAATGGCACAG 
WDR62-AMP.27-R TCTGGGCATCACCTTCTACC 
Appendix 6 
Pedigrees of 14 consanguineous families in which ASPM is Sanger sequenced without 
performing linkage analysis. These families were mostly ascertained from the North West part 
of Pakistan 
 
1. Pedigree MCP103 
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2. Pedigree MCP96     3. Pedigree MCP135 
 
 
   
4. Pedigree MCP136     5. Pedigree MCP138 
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6. Pedigree MCP137 
 
7. Pedigree MCP139 
 
8. Pedigree MCP140 
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9. Pedigree MCP141 
   
10. Pedigree MCP143     11. Pedigree MCP174 
 
12. Pedigree MCP175 
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13. Pedigree MCP176 
 
 
  
14. Pedigree MCP177 
 
 
 
Appendix 
 130 
Appendix 7 
Primer sequences related to pyrosequncing, RT-PCR, quantitative PCR and capillary 
electrophoresis in PLK4. 
 
Pyrosequencing 
PLK4-Ex16CT-F BiotiN-TAATGTGCTTTTTGGGACTCTCA 
PLK4-Ex16CT-R AAGGATGGAAGACAGACACTGTAA 
PLK4-Ex16CT-S TTTCATTTTCTCCATACCT   
RT-PCR and capillary electrophoresis  
PLK4-CFr-F  FAM-AATGTTGGTTGGGCTACACAG 
PLK4-CFr-R  CATCAAAAGGATGGAAGACAGAC 
Sanger sequencing 
PLK4-Ex16-F   ttttctgaggtgcctcttg 
PLK4-EX16-R   CATCAAAAGGATGGAAGACAGAC 
Quantitative PCR 
GAPDH-F         CCAGGTGGTCTCCTCTGACTTC 
GAPDH-R         GGTGTCGCTGTTGAAGTCAGA 
PLK4-QT-F1        GGAGCTGTGTGGGTTCAGTT 
PLK4-QT-R1        CATCAAAAGGATGGAAGACAGA 
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10. Abbreviations 
Asp   Abnormal spindle gene 
ASPM    Abnormal Spindle-like Microcephaly-associated 
Asl   Asterless 
APS   Adenosine 5’ Phosphosulfate 
ATR    Ataxia Telangiectasia Mutated  
BRCT   Breast cancer 1(BRCA1) C-terminal 
CDK5RAP2  Cyclin Dependent Kinase 5 Regulatory Associated Protein 2 
CDK6   Cyclin-dependent Kinase 6 
CEP135  Centrosomal protein 135 kDa  
CENPJ   Centromere Protein J 
CEP152  Centrosomal Protein of 152 kDa 
CNV   Copy Number Variation 
CPAP   Centrosomal protein 4.1- associated protein  
CT   Computerized tomography  
CMV   Cytomegalovirus 
CPB   Cryptic Polo Box 
DNA   Deoxyribonucleic acid 
DAPI   4’, 6-Diamidino-2’-phenylindole 
dNTP   Deoxyribonucleotide Triphosphate 
DDC1   DNA damage checkpoint 1 
DMEM   Dulbecco´s Modified Eagle´s Medium 
DMSO   Dimethyl Sulfoxide 
DTT   Dithiothreitol 
ECL    Enhanced chemiluminescence 
FBS   Fetal bovine serum 
γTuRC   γ-tubulin ring complex 
HC   Head circumference 
Kb   Kilobases 
kDa   kilodaltons 
LMW   Low Molecular Weight 
LD   Linkage Disequilibrium  
LOD   Logarithm of the odds 
MCPH   Autosomal recessive primary microcephaly 
MEF   Mouse Embryonic Fibroblasts  
MGS   Meier Gorlin Syndrome 
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mRNA   Messenger Ribonucleic Acid 
MRI   Magnetic resonance imaging 
MCPH1  Autosomal recessive primary microcephaly locus 1 
MCPH2  Autosomal recessive primary microcephaly locus 2 
MCPH3  Autosomal recessive primary microcephaly locus 3 
MCPH4  Autosomal recessive primary microcephaly locus 4 
MCPH5  Autosomal recessive primary microcephaly locus 5 
MCPH6  Autosomal recessive primary microcephaly locus 6 
MCPH7  Autosomal recessive primary microcephaly locus 7 
MCPH8  Autosomal recessive primary microcephaly locus 8 
MCPH9  Autosomal recessive primary microcephaly locus 9 
MCPH10  Autosomal recessive primary microcephaly locus 10 
MCPH11  Autosomal recessive primary microcephaly locus 11 
MCPH12  Autosomal recessive primary microcephaly locus 12 
MCPH13  Autosomal recessive primary microcephaly locus 13 
MOPD   microcephalic osteodysplastic primordial dwarfism 
MPD   Microcephalic Primordial Dwarfism 
MRI   Magnetic Resonance Imaging 
MTOC   Microtubule Organising Centre 
NCBI   National Center for Biotechnology Information 
NE   Neuroepithelial 
NGS    Next Generation Sequencing  
NMR    Nuclear magnetic resonance 
ORF    Open Reading Frame 
OFC   Occipital Frontal Circumference 
PB3   Polo Box Domain 3 
PBS   Phosphate buffered saline 
PCC   Premature Chromosome Condensation 
PCM   Pericentriolar matrix 
PCNT   Pericentrin 
PCR   Polymerase chain reaction 
PEI   polyethylenimine 
PFA   paraformaldehyde 
PIC   Proteinase Inhibitor Cocktail 
Plk4   Polo-like-kinase 4 
PKU   Phenylketonuria 
PSQ   Pyromark Assay Design 
Abbreviations 
 133 
RT-PCR  Reverse transcriptase PCR 
SAP   Shrimp Alkaline Phosphatase  
SD   Standard deviation 
SDS   Sodium Dodecyl Sulphate 
SDS-PAGE   SDS-polyacrylamide gel electrophoresis  
STR    Short tandem repeat 
SNP   Single Nucleotide Polymorphism 
SVZ   Subventricular zone 
STIL/SIL  SCL/TAL1 interrupting locus 
TBS   Tris-buffered saline 
UV    Ultra-Violet 
V   Volt 
VZ   Ventricular zone 
WDR62  WD repeat domain 62 
WHO   World Health Organization 
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